<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004296.pub2" GROUP_ID="STROKE" ID="267603013013482884" MERGED_FROM="" MODIFIED="2008-10-08 16:29:42 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-10-08 16:29:42 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Triflusal for preventing serious vascular events in people at high risk</TITLE>
<CONTACT MODIFIED="2008-10-08 16:29:42 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>João</FIRST_NAME><LAST_NAME>Costa</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Neurologist</POSITION><EMAIL_1>joaoncosta@sapo.pt</EMAIL_1><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+ 351 91 7532125</PHONE_1><PHONE_2>+ 351 21 7973453</PHONE_2><FAX_1>+ 351 21 7819688</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-08 16:29:42 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>João</FIRST_NAME><LAST_NAME>Costa</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Neurologist</POSITION><EMAIL_1>joaoncosta@sapo.pt</EMAIL_1><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+ 351 91 7532125</PHONE_1><PHONE_2>+ 351 21 7973453</PHONE_2><FAX_1>+ 351 21 7819688</FAX_1></ADDRESS></PERSON><PERSON ID="16470" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>José</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Ferro</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>jmferro@fm.ul.pt</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Santa Maria Hospital</ORGANISATION><ADDRESS_1>Av Prof Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-045</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>351-21-7974956</PHONE_1><FAX_1>351-21-7957474</FAX_1></ADDRESS></PERSON><PERSON ID="16509" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jordi</FIRST_NAME><LAST_NAME>Matias-Guiu</LAST_NAME><EMAIL_1>matias_jor@gva.es</EMAIL_1><ADDRESS><DEPARTMENT>Service of Neurology</DEPARTMENT><ORGANISATION>Hospital General Universitario de Alicante</ORGANISATION><ADDRESS_1>Maestro Alonso 109</ADDRESS_1><CITY>Alicante</CITY><ZIP>E03010</ZIP><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON><PERSON ID="16428" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jose</FIRST_NAME><LAST_NAME>Alvarez-Sabin</LAST_NAME><EMAIL_1>alsa@hg.vhebron.es</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Vall d'Hebron Hospital</ORGANISATION><CITY>Barcelona</CITY><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON><PERSON ID="16548" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ferran</FIRST_NAME><LAST_NAME>Torres</LAST_NAME><ADDRESS><DEPARTMENT>Laboratorio de Bioestadistica y Epidemiologia</DEPARTMENT><ORGANISATION>Universitat Autonoma de Barcelona</ORGANISATION><CITY>Barcelona</CITY><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-08 14:38:21 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="22" MONTH="2" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="10" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="8" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-08 14:38:35 +0100" MODIFIED_BY="Hazel Fraser"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Centro de Estudos Egas Moniz, Lisbon Faculty of Medicine</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-08 14:50:53 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-10-08 14:39:47 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-10-08 14:39:47 +0100" MODIFIED_BY="Hazel Fraser">Triflusal for preventing serious vascular events in people at high risk</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-08 14:39:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>Triflusal is not clearly better than aspirin for preventing serious vascular events such as strokes, heart attacks and deaths from vascular disease. Triflusal and aspirin are drugs that prevent blood clots forming. When blood clots form in arteries and block the flow of blood, they can cause a stroke, heart attack or other serious circulatory problems. These are called serious vascular events. People who have had a stroke, a heart attack or symptoms of blood clots in other arteries are at high risk of experiencing further vascular events. There is strong evidence that in people who have had a vascular event, aspirin reduces the risk of further events. This review compared the effects of triflusal with aspirin in people who had had a vascular event. It did not find any evidence that triflusal was definitely better than aspirin for preventing further serious vascular events, although triflusal did seem to cause fewer bleeding complications than aspirin.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-08 14:45:54 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND>
<P>Aspirin is the standard treatment for secondary prevention of stroke and other vascular events. Several studies suggest that triflusal may have a better safety profile.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine in people at high risk of vascular events whether triflusal is an effective and safe treatment for primary and secondary prevention of serious vascular events.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-08 14:39:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the trials registers of the following Cochrane Review Groups: Stroke Group (last searched October 2004), Heart Group, Peripheral Vascular Diseases Group and Metabolic and Endocrine Disorders Group (last searched May 2003). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>Issue 2, 2003), MEDLINE (1977 to 2003) and EMBASE (1980 to 2003). We searched reference lists and contacted researchers in the field, authors of relevant trials and the drug manufacturer.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised and quasi-randomised studies comparing triflusal with placebo or aspirin in people at high risk of vascular events.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-10-08 14:45:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two authors independently assessed trial quality and extracted data. The primary outcome was a serious vascular event (non-fatal acute myocardial infarction (AMI), non-fatal ischemic or hemorrhagic stroke, or vascular death). Other efficacy and safety measures collected were frequency of different vascular events, adverse events, minor and major hemorrhages.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-10-08 14:45:52 +0100" MODIFIED_BY="Hazel Fraser">
<P>(1) Aspirin versus triflusal: five studies enrolled patients with stroke or transient ischemic attack (TIA) (4 trials; 2944 patients; followed for 6 to 47 months) or AMI (one trial; 2275 patients; followed for 35 days). Entry criteria were similar within each subgroup of patients. Patient groups were appropriately selected and well matched. The primary outcome in all trials was a composite outcome of vascular events. Trials had no important bias except in one study (217 patients). For the primary outcome of a serious vascular event there was no significant difference between triflusal and aspirin; the odds ratio (OR) was 1.04 (95% confidence interval (CI) 0.87 to 1.23). Significant differences were found for frequency of hemorrhages, both minor (OR 1.60, 95% CI 1.31 to 1.95) and major (OR 2.34, 95% CI 1.58 to 3.46) and for non-hemorrhagic gastrointestinal adverse events (OR 0.84, 95% CI 0.75 to 0.95). Sensitivity analysis of well versus poorly allocated trials showed no significant differences. (2) Triflusal versus placebo: two trials enrolled patients with unstable angina (281 patients) or peripheral arteriopathy (122 patients), who were followed for 6 months. Triflusal was associated with a reduction in serious vascular events (OR 2.29, 95% CI 1.01 to 5.19; OR greater than 1 favours triflusal) and with a higher frequency of adverse events (OR 1.68, 95% CI 1.00 to 2.80).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>No significant differences were found between triflusal and aspirin for secondary prevention of serious vascular events in patients with stroke or TIA and AMI. However, our review cannot exclude moderate differences in efficacy. Triflusal was associated with a lower risk of hemorrhagic complications.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-08 14:50:53 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND>
<P>Antiplatelet therapy, mainly aspirin, has proven to be effective in reducing serious vascular events (non-fatal myocardial infarction, non-fatal stroke, or vascular death) among patients at high risk of occlusive vascular events because of previous myocardial infarction, acute myocardial infarction, previous stroke or transient ischemic attack (TIA), acute stroke or other high risk. The absolute benefit in patients with previous stroke, TIA, or myocardial infarction is 36 to 38 fewer vascular events per 1000 patients who are treated for two years. The absolute benefit substantially outweighs the small risk of either intracranial or major extracranial bleeding (<LINK REF="REF-ATC" TYPE="REFERENCE">ATC</LINK>). Among antiplatelet agents, aspirin is still considered the standard treatment for the secondary prevention of stroke and other vascular events.</P>
<P>Other antiplatelet agents, such as ticlopidine and clopidogrel or drug combinations (for example, aspirin and dipyridamole), have also been evaluated by large clinical trials in this clinical area (<LINK REF="REF-CAPRIE" TYPE="REFERENCE">CAPRIE</LINK>; <LINK REF="REF-Diener-1996" TYPE="REFERENCE">Diener 1996</LINK>; <LINK REF="REF-Hankey-2000" TYPE="REFERENCE">Hankey 2000</LINK>). To detect moderate treatment effects, such as might be expected in a trial comparing aspirin with control, requires a large sample size. To reliably detect the relatively small difference between aspirin and another antiplatelet agent requires an even larger sample size. There have been relatively few large-scale randomised trials (i.e. involving 10,000 or more patients), comparing aspirin with another antiplatelet agent (<LINK REF="REF-ATC" TYPE="REFERENCE">ATC</LINK>). Such evidence exists only for clopidogrel versus aspirin.</P>
<P>Triflusal is an antiplatelet agent that is structurally related to aspirin and exerts its antithrombotic effect by acting on various targets involved in platelet aggregation and vascular inflammatory processes (<LINK REF="REF-De-la-Cruz-1995" TYPE="REFERENCE">De la Cruz 1995</LINK>; <LINK REF="REF-Fernandez-1999" TYPE="REFERENCE">Fernandez 1999</LINK>; <LINK REF="REF-Garc_x00ed_a-1986" TYPE="REFERENCE">García 1986</LINK>). In addition, triflusal increases nitric oxide synthesis in neutrophils resulting in increased vasodilatory potential (<LINK REF="REF-Sanchez-2000" TYPE="REFERENCE">Sanchez 2000</LINK>). The pharmacological effects of triflusal have already been investigated in different conditions (<LINK REF="STD-Auteri-1995" TYPE="STUDY">Auteri 1995</LINK>; <LINK REF="REF-Cruz_x002d_Fernandez-2000" TYPE="REFERENCE">Cruz-Fernandez 2000</LINK>; <LINK REF="STD-Guiteras-1989" TYPE="STUDY">Guiteras 1989</LINK>; <LINK REF="REF-Matias_x002d_Guiu-1997" TYPE="REFERENCE">Matias-Guiu 1997</LINK>; <LINK REF="REF-Matias_x002d_Guiu-2001" TYPE="REFERENCE">Matias-Guiu 2001</LINK>; <LINK REF="STD-Masotti-1991" TYPE="STUDY">Masotti 1991</LINK>; <LINK REF="REF-Plaza-1993" TYPE="REFERENCE">Plaza 1993</LINK>; <LINK REF="STD-Putz-1991" TYPE="STUDY">Putz 1991</LINK>).</P>
<P>Unlike aspirin, triflusal did not increase bleeding time (<LINK REF="REF-De-la-Cruz-1988" TYPE="REFERENCE">De la Cruz 1988</LINK>). In several trials triflusal was associated with a lower frequency of hemorrhagic complications (<LINK REF="REF-Cruz_x002d_Fernandez-2000" TYPE="REFERENCE">Cruz-Fernandez 2000</LINK>; <LINK REF="REF-Matias_x002d_Guiu-1997" TYPE="REFERENCE">Matias-Guiu 1997</LINK>; <LINK REF="REF-Matias_x002d_Guiu-2001" TYPE="REFERENCE">Matias-Guiu 2001</LINK>). However, the total number of serious hemorrhages registered in each of these trials was small. No significant differences were found in a trial comparing the preventive effect of triflusal or aspirin in patients with previous minor stroke or TIA (<LINK REF="REF-Matias_x002d_Guiu-2001" TYPE="REFERENCE">Matias-Guiu 2001</LINK>). However, these trials were also small and the confidence intervals were wide so that findings were compatible with either a small benefit or disadvantage for each of the drugs. </P>
<P>Because of the suggestion of a safer profile for triflusal and the uncertainty of its efficacy when compared with aspirin, we thought it was useful to perform a systematic review of all randomised controlled trials that assessed triflusal for preventing serious vascular events in people at high risk.<BR/>
</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of triflusal on the risk of serious vascular events and of major bleeding complications compared with placebo and with aspirin, in people at high risk of vascular events.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-08 14:48:50 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-10-08 14:46:51 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>Randomised trials of triflusal versus placebo and triflusal versus aspirin. Trials with poor allocation concealment (quasi-randomised) were also included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with:<BR/>(1) previous ischemic vascular events (transient ischemic attacks (TIAs), ischemic stroke, myocardial infarction);<BR/>(2) acute ischemic events (acute stroke, acute myocardial infarction);<BR/>(3) coronary heart disease (unstable angina, stable angina, heart failure, coronary angioplasty, coronary artery bypass surgery);<BR/>(4) high risk of embolism (atrial fibrillation, cardiac valve disease, cardiac valve surgery);<BR/>(5) peripheral artery disease (intermittent claudication, peripheral grafting, peripheral angioplasty);<BR/>(6) other high-risk patients (haemodialysis, diabetes, carotid disease).</P>
<P>Trials in which the pathological type of stroke was not confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) before entry were included, as the majority of such strokes are ischemic (<LINK REF="REF-Bamford-1990" TYPE="REFERENCE">Bamford 1990</LINK>). Both genders and all ages were considered irrespective of the severity and time elapsed after the event and of the duration of the symptoms or condition.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Treatment with oral triflusal (any dosage) versus placebo and treatment with oral triflusal (any dosage) versus oral aspirin (any dosage). The minimum duration of treatment was one month.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-08 14:46:51 +0100" MODIFIED_BY="Hazel Fraser">
<P>For each trial, the number of patients originally randomly allocated to each treatment group was identified. In both groups, the number of patients that had each outcome was considered. The timing of outcome measures was at the end of treatment, meaning that outcomes were included if they occurred within the follow-up treatment period regardless of whether patients were still actually taking their allocated treatment.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<P>A serious vascular event is defined as non-fatal myocardial infarction, non-fatal ischemic or hemorrhagic stroke, or vascular death. Vascular death is defined as cardiac, cerebrovascular, venous thromboembolic, hemorrhagic, or from some other vascular event. Deaths from unknown cause will be included because most deaths in high-risk patients are likely to be due to vascular causes. In order to allow the number of serious vascular events to be derived by adding the numbers of non-fatal myocardial infarctions, non-fatal strokes, and vascular deaths, we considered an event non-fatal if the patient survived at least one month from the inclusion event (or the person died of a definitely non-vascular cause). All events classified as probable or definite were included. If, during the trial, a patient experienced more than one type of non-fatal outcome, both events were recorded but such patients contributed only once to the composite outcome of serious vascular event. If, during the trial, a patient experienced more than one non-fatal event of the same type, or more than one pathological type of stroke (for example, a hemorrhagic stroke and an ischemic stroke), only the first was considered for the primary outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Non-fatal ischemic stroke</LI>
<LI>Non-fatal stroke (ischemic, hemorrhagic, and unknown)</LI>
<LI>All ischemic strokes (fatal, and non-fatal)</LI>
<LI>All strokes (fatal, non-fatal, ischemic, hemorrhagic, and unknown)</LI>
<LI>Non-fatal myocardial infarction</LI>
<LI>All myocardial infarctions (fatal, and non-fatal)</LI>
<LI>Vascular death</LI>
<LI>Non-vascular death</LI>
<LI>All deaths (vascular, and non-vascular)</LI>
<LI>Any intracranial hemorrhage (including intracerebral, subdural, subarachnoid, and extradural hemorrhages)</LI>
<LI>Major extracranial hemorrhage (fatal; or severe enough to lead to hospital admission, transfusion, or surgery)</LI>
<LI>All serious hemorrhages (any intracranial hemorrhage, or major extracranial hemorrhage)</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-08 14:48:11 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>Relevant trials were identified in the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator in October 2004. In addition, we contacted other relevant Cochrane review groups to request searches of their trials registers in May 2003: Heart Group, Peripheral Vascular Diseases Group and Metabolic and Endocrine Disorders Group. We also searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library Issue 2, 2003</I>), MEDLINE (1977 to February 2003) (the patent for triflusal was registered in 1977) and EMBASE (1980 to February 2003). Titles, keywords, and abstracts of the citations downloaded from the electronic searches were screened, and full copies of reports of potential trials were obtained for further assessment. The reference lists of located trials and antiplatelet review articles were searched. Authors of published trials were contacted for further information and unpublished data. We also contacted the drug manufacturer (J Uriach &amp; Cía SA) to try to identify any further published or unpublished studies.</P>
<P>The database search strategies are detailed below:</P>
<P>MEDLINE (Ovid) and CENTRAL</P>
<P>1. (triflusal or disgren or tecnosal or triflux or aflen or ur-1501).tw.</P>
<P>EMBASE (Ovid)</P>
<P>1. Triflusal/<BR/>2. (triflusal or disgren or tecnosal or triflux or aflen or ur-1501).tw.<BR/>3. 1 or 2</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-08 14:48:50 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two authors (João Costa, José M. Ferro) independently assessed the studies identified by the search strategy in order to identify potential trials for the review, according to the criteria outlined above. Disagreements about inclusions were resolved by discussion.</P>
<P>The authors independently assessed the full papers for methodological quality by extracting details of randomisation methods, blinding of treatments and assessments, whether intention-to-treat analysis was possible from the published data, whether treatment groups were comparable with regard to major prognostic risk factors for outcomes, the number of patients excluded or lost to follow up in each treatment group, definition of outcomes, and entry and exclusion criteria.</P>
<P>Data was sought on the number of patients with each outcome or event by allocated treatment group, irrespective of compliance, and whether or not the patient was subsequently deemed ineligible or otherwise excluded from treatment or follow up, to allow an intention-to-treat analysis. We had access to the individual patient data.</P>
<P>Two authors (João Costa, José M. Ferro) independently abstracted eligible data onto standardised forms, which were cross-checked for accuracy and amalgamated. Disagreements about inclusion were resolved by discussion. The global quality of included trials was assessed by Jadad's scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Publication bias was checked by the funnel plot method.</P>
<P>Results were reported as Peto fixed-effect odds ratios (<LINK REF="REF-APT" TYPE="REFERENCE">APT</LINK>), using the Cochrane Review Manager software, RevMan 4.2. Heterogeneity between trial results was tested using a standard chi-squared test, and possible causes of any heterogeneity were discussed. Where indicated, the number of events avoided for every 1000 patients treated was calculated from the Peto odds ratio.</P>
<P>The following sensitivity and subgroup analyses were performed.<BR/>
</P>
<UL>
<LI>Well/poorly allocated trials.</LI>
<LI>Category of the trial: previous TIA or stroke, acute myocardial infarction.</LI>
<LI>Duration of the treatment: more or less than six months.</LI>
</UL>
<P>For subgroup analyses we used the method described by Deeks that is based on the test for heterogeneity chi-squared statistics (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). Since only two subgroups were considered we also looked at the overlap of the confidence intervals.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-08 14:50:13 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-10-08 14:49:15 +0100" MODIFIED_BY="Hazel Fraser">
<P>See the 'Characteristics of included studies' and 'Characteristics of excluded studies' tables.</P>
<SUBSECTION>
<HEADING LEVEL="3">Aspirin versus triflusal for secondary prevention of serious vascular events</HEADING>
<P>We included five studies comparing triflusal with aspirin (<LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK>; <LINK REF="STD-Smirne-1994" TYPE="STUDY">Smirne 1994</LINK>; <LINK REF="STD-TACIP" TYPE="STUDY">TACIP</LINK>; <LINK REF="STD-TAPIRSS" TYPE="STUDY">TAPIRSS</LINK>; <LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK>). All these randomised controlled trials (RCTs) were multicentre studies, conducted in Spain, Portugal, Italy and Argentina, and were published between 1994 and 2004. The <LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK> trial had a sequential study design; the other studies had a classical parallel design. One trial (<LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK>) included 2275 patients with acute myocardial infarction (AMI) (mean age: 61 years old) who were followed for 35 days. The other four studies included 2944 patients with previous non-disabling ischemic stroke and/or transient ischemic attack (TIA) (mean age: 65 years old) with a follow up ranging from six (<LINK REF="STD-Smirne-1994" TYPE="STUDY">Smirne 1994</LINK>) to 47 months (<LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK>). Overall, 5219 patients were enrolled in these five studies. Two studies (<LINK REF="STD-TACIP" TYPE="STUDY">TACIP</LINK>; <LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK>) enrolled 84% of these patients.</P>
<P>Entry criteria did not differ considerably between the trials that included patients with previous ischemic stroke or TIA. The only exception was the <LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK> study that included patients aged less than 50 years old. Four studies excluded patients with severe or disabling neurologic deficit, and ischemic stroke or TIA with a probable non-atherothrombotic cause (<LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK>; <LINK REF="STD-Smirne-1994" TYPE="STUDY">Smirne 1994</LINK>; <LINK REF="STD-TACIP" TYPE="STUDY">TACIP</LINK>; <LINK REF="STD-TAPIRSS" TYPE="STUDY">TAPIRSS</LINK>). Within studies, patients were generally well matched for demographics, vascular risk factors, and characteristics of the qualifying event between the triflusal and aspirin arms.</P>
<P>The <LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK> study compared 900 mg daily of triflusal with 330 mg daily of aspirin. All other studies compared 600 mg daily of triflusal with 300 to 325 mg daily of aspirin.</P>
<P>The primary outcome for all trials was a composite outcome that included the first occurrence of one serious vascular event. The type of events considered in each trial was different and included death, vascular death, non-fatal stroke, non-fatal cerebrovascular event (either ischemic or hemorrhagic), and non-fatal AMI. Criteria for these diagnoses were accurate in all trials and were based on clinical grounds and complementary examinations (electrocardiogram, biochemical, brain CT scan).</P>
<P>In the two major trials (<LINK REF="STD-TACIP" TYPE="STUDY">TACIP</LINK>; <LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK>) study medication was administered early and was permanently discontinued for reasons other than the occurrence of a primary outcome in 19% and 28%, respectively. The number of patients and the reasons for study drug discontinuation were similar in both groups in all trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Triflusal versus placebo for secondary prevention of serious vascular events</HEADING>
<P>We included two studies comparing triflusal with placebo (<LINK REF="STD-Auteri-1995" TYPE="STUDY">Auteri 1995</LINK>; <LINK REF="STD-GEAIT" TYPE="STUDY">GEAIT</LINK>). Both RCTs were multicentre studies, conducted in Spain (<LINK REF="STD-GEAIT" TYPE="STUDY">GEAIT</LINK>) and Italy (<LINK REF="STD-Auteri-1995" TYPE="STUDY">Auteri 1995</LINK>), and were published in 1993 and 1995, respectively. Both had a parallel design.</P>
<P>The <LINK REF="STD-GEAIT" TYPE="STUDY">GEAIT</LINK> trial included 281 patients, aged less than 70 years old, with unstable angina who were admitted to a coronary unit and followed for six months. Patients were generally well matched for demographics, vascular risk factors, and characteristics of the qualifying event between the triflusal and placebo arms. Exceptions were hematocrit value, history of hypertension, and concomitant use of calcium antagonists, which were higher in the placebo group. This trial compared 900 mg daily of triflusal with placebo. The primary outcome was a composite outcome that included the first occurrence of cardiac death, vascular death, or non-fatal AMI. Criteria for these diagnoses were accurate and were based on clinical grounds and complementary examinations (electrocardiogram, biochemical, brain CT scan). Numbers and reasons for withdrawals were similar between groups (11% in each arm).</P>
<P>The Auteri trial (<LINK REF="STD-Auteri-1995" TYPE="STUDY">Auteri 1995</LINK>) included 122 patients with chronic obliterative peripheral arteriopathy (stage II Lériche-Fontaine) who were followed for six months. Patients were generally well matched for demographics, vascular risk factors, and characteristics of the qualifying event between the triflusal and placebo arms. This trial compared 600 mg daily of triflusal with placebo. The primary outcome was total walking distance determined through effort tests on the treadmill. One patient in the placebo group and four patients in the triflusal group withdrew early from the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies</HEADING>
<P>We excluded 16 studies. Of these, six were prospective studies without a control group (<LINK REF="STD-Arcas-1981" TYPE="STUDY">Arcas 1981</LINK>; <LINK REF="STD-De-la-Torre-1984" TYPE="STUDY">De la Torre 1984</LINK>; <LINK REF="STD-Garay-Lillo-1987" TYPE="STUDY">Garay Lillo 1987</LINK>; <LINK REF="STD-Kwon-1996" TYPE="STUDY">Kwon 1996</LINK>; <LINK REF="STD-Sala_x002d_Planell-1981" TYPE="STUDY">Sala-Planell 1981</LINK>; <LINK REF="STD-Zan-2002" TYPE="STUDY">Zan 2002</LINK>). Two studies were case-control studies without randomisation (<LINK REF="STD-Lanas-2003" TYPE="STUDY">Lanas 2003</LINK>; <LINK REF="STD-Masotti-1991" TYPE="STUDY">Masotti 1991</LINK>). Two other studies were subgroup analyses of trials already included (<LINK REF="STD-Bescos-1999" TYPE="STUDY">Bescos 1999</LINK>; <LINK REF="STD-Pontes-2001" TYPE="STUDY">Pontes 2001</LINK>). One study compared triflusal with acenocoumarol in healthy volunteers (<LINK REF="STD-Perez-2002" TYPE="STUDY">Perez 2002</LINK>). We excluded six randomised trials because outcomes were evaluated before one month of follow up (<LINK REF="STD-Guiteras-1989" TYPE="STUDY">Guiteras 1989</LINK>; <LINK REF="STD-Monreal-1995" TYPE="STUDY">Monreal 1995</LINK>; <LINK REF="STD-Putz-1991" TYPE="STUDY">Putz 1991</LINK>), no placebo or aspirin group were included (<LINK REF="STD-Alvarez_x002d_Sabin-1996" TYPE="STUDY">Alvarez-Sabin 1996</LINK>; <LINK REF="STD-NASPEAF-2004" TYPE="STUDY">NASPEAF 2004</LINK>), or the study population was not at high vascular risk (<LINK REF="STD-Cesarone-1999" TYPE="STUDY">Cesarone 1999</LINK>). See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All studies stated that they randomised patients between the treatment options, and described the precise method of randomisation and details of concealment of allocation. The allocation concealment was adequate for all trials except the <LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK> trial that randomised patient by alternative days. Except for this trial, all the other studies were not subject to selection bias. All except one trial (<LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK>) were double blind throughout, using an identical aspirin or placebo, so it was unlikely that there was important performance or attrition bias. All studies reported the reasons for patients leaving the trials. However, there were a significant number of patients that prematurely discontinued the study medication. Although withdrawals were evenly distributed between groups, we cannot exclude the occurrence of attrition bias. In all trials the data was analysed blind making detection bias unlikely. We did not detect any selective reporting of results. Data were analysed on a per-protocol basis in two studies (<LINK REF="STD-Auteri-1995" TYPE="STUDY">Auteri 1995</LINK>; <LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK>) and the remaining five studies used an intention-to-treat analysis.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-08 14:50:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>We were able to perform a meta-analysis with studies included in this review. Since we aimed to compare triflusal with aspirin and with placebo, two meta-analyses were performed, one for each comparison.</P>
<P>Although most studies used a composite outcome as the primary endpoint, the type of events in each trial varied. Another important issue was missing data for some of the outcomes that we proposed to study in this systematic review. Both aspects could have been responsible for the inclusion of misleading data, since a patient could be counted twice for our primary outcome. We were able to overcome this problem as we had access to the individual patient data from all the original trials except for the <LINK REF="STD-Smirne-1994" TYPE="STUDY">Smirne 1994</LINK> study. These data were kindly provided by Grupo Uriach (Barcelona, Spain), which was the sponsor of most of these trials.</P>
<P>We examined objective outcome measures of efficacy and safety. With a few exceptions listed below, objective primary and secondary outcomes of efficacy did not show significant differences between aspirin and triflusal but showed the superiority of triflusal over placebo. Important differences were found, however, regarding objective outcomes of safety and tolerability between aspirin and triflusal. We did not study subjective outcome measures or quality of life changes since no data were available in the trials for analysis. Funnel plots did not suggest selective reporting of trials. Where differences were found, we calculated the number needed to treat (NNT) for efficacy outcomes, and the number needed to harm (NNH), and number of events avoided for 1000 patients treated for safety outcomes.</P>
<P>The NNT (the number of patients who must be treated to prevent one adverse outcome) and the NNH (the number of patients who must be treated to cause one additional adverse effect) are widely used measures. However, the NNTs derived from meta-analysis may be misleading because of variation in the event rates in trials, differences in the outcomes considered, effects of secular trends on disease risk, and differences in clinical setting (<LINK REF="REF-Smeeth-1999" TYPE="REFERENCE">Smeeth 1999</LINK>). There is debate concerning methods for calculating the NNTs and the NNHs from results of systematic reviews. We have calculated the NNTs from meta-analysis estimates and have not treated the data as if they arose from a single trial; the last approach is more prone to bias, especially when significant imbalances between groups within one or more trials in the meta-analysis exists (<LINK REF="REF-Altman-2002" TYPE="REFERENCE">Altman 2002</LINK>). This was not the case in our meta-analysis and results from both methods of calculation produced very similar results (data not shown).</P>
<SUBSECTION>
<HEADING LEVEL="3">Aspirin versus triflusal for secondary prevention of serious vascular events</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Objective outcomes of efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<P>No significant differences were found for the primary outcome (odds ratio (OR) 1.04, 95% confidence interval (CI) 0.87 to 1.23). However, the CI was wide and we could not exclude the possibility that triflusal may be 13% worse or 23% better than aspirin. Also, there appeared to be no significant differences for each of the individual outcomes that contributed to the primary outcome: vascular death (OR 1.11, 95% CI 0.86 to 1.45), non-fatal stroke (OR 1.10, 95% CI 0.86 to 1.40), and non-fatal AMI (OR 0.90, 95% CI 0.61 to 1.31).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>In general, we found no significant differences for the secondary outcomes. Exceptions, all favouring triflusal, were non-fatal hemorrhagic stroke (OR 2.83, 95% CI 1.2 to 6.68; NNT 238, 95% CI 181 to 923), fatal and non-fatal hemorrhagic stroke (OR 2.15, 95% CI 1.15 to 4.04; NNT 171, 95% CI 121 to 702), and fatal ischemic stroke (OR 2.71, 95% CI 1.12 to 6.55; NNT 260, 95% CI 193 to 1531). However, although it did not reach significance, aspirin had a lower risk of acute fatal myocardial infarction (OR 0.30, 95% CI 0.09 to 1.02). Since only 10 events were registered for this outcome and no difference existed for the outcome acute fatal and non-fatal myocardial infarction (OR 1.01, 95% CI 0.63 to 1.63), these tendencies might be due to chance. The same hypothesis should be considered for the outcome fatal ischemic stroke where triflusal was associated with a significantly lower risk compared with aspirin.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Objective outcomes of safety and tolerability</HEADING>
<P>We found significant differences for the outcomes of safety and tolerability. Triflusal was associated with less serious adverse events related to medication and with fewer minor and major hemorrhagic complications (see figures and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for details). On the other hand, aspirin was associated with fewer non-hemorrhagic gastrointestinal adverse events (nausea, vomiting, dyspepsia, heart burn, abdominal pain, diarrhoea, constipation, gastritis, peptic ulcer). No differences were found for the number of patients with at least one adverse event. The reader should note that the outcomes number of patients with at least one adverse event, serious adverse events related to medication, any hemorrhagic adverse event, any minor hemorrhage, anaemia, and non-hemorrhagic gastrointestinal adverse events were not pre-specified in the protocol and should be regarded as post-hoc analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity and subgroup analyses</HEADING>
<P>As planned in the protocol, we performed a sensitivity analysis for well versus poorly allocated trials. We excluded two studies from the primary analysis. The <LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK> trial had poor allocation concealment, and the <LINK REF="STD-Smirne-1994" TYPE="STUDY">Smirne 1994</LINK> study had adequate allocation concealment but its primary outcome event was a composite outcome related to prevention of reversible ischemic attacks, stroke and vascular death, which was not exactly the same as our primary outcome. Since we did not have access to individual patient data from this study we could not be as accurate as for the other studies in our primary outcome. After excluding these trials there were no significant changes in the results for the primary outcome (Peto OR 1.00, 95% CI 0.83 to 1.20). For those efficacy and safety outcomes where differences were found, the only significant changes were for the outcomes reporting on the number of patients with ischemic fatal stroke (Peto OR 2.17, 95% CI 0.73 to 6.44) and for the number of patients with serious adverse events related to medication (Peto OR 1.27, 95% CI 0.94 to 1.72).</P>
<P>When performing the meta-analysis we also did a subgroup analysis by presenting the results according to the category of the trials based on the two types of patients studied (previous stroke or TIA and AMI). By doing this, we were also performing another subgroup analysis since the trial that included patients with AMI was the one with the shorter duration of treatment (35 days) as compared with the trials that included patients with stroke or TIA, which had a duration of treatment of at least six months (in three of these four trials, responsible for 94% of these patients, the minimum follow up was one year). Results from this subgroup analysis should be regarded with caution since only one trial was available in one subgroup. Although there were differences in these two subgroups for many efficacy and safety outcomes they were always of the same type, with the AMI subgroup showing no significant differences in the outcomes studied. Since the results of the AMI subgroup always showed the same tendency as the stroke or TIA subgroup results, and no significant heterogeneity was found between the trials of the two subgroups, these differences are probably explained by the fewer patients included in the AMI subgroup that precluded a statistically significant result. The full results can be seen in the meta-analysis plots.</P>
<P>We tested heterogeneity between trials results using a standard chi-squared test. Assuming that significant statistic heterogeneity is less than 1 in 10, we found no evidence of heterogeneity.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Triflusal versus placebo for secondary prevention of serious vascular events</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Objective outcomes of efficacy</HEADING>
<P>We found significant differences in the efficacy outcomes between placebo and triflusal. We were not able to perform as many comparisons between triflusal and placebo as we did between triflusal and aspirin. This was because less data were available for many outcomes. However, we were able to quantify our primary outcome, which showed a significant result favouring triflusal (OR 2.29, CI 95% 1.01 to 5.19; NNT 22, CI 95% 15 to 1304). Also, triflusal was associated with fewer non-fatal AMIs (OR 2.94, 95% CI 1.25 to 6.88; NNT 19, 95% CI 15 to 64). On the other hand, there were more adverse events in the triflusal group (OR 0.60, 95% CI 0.36 to 1.00). The reader should note that for the objective outcomes of efficacy, an odds ratio higher than 1 favours triflusal.</P>
<P>No sensitivity or subgroup analyses were performed in this meta-analysis.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-08 14:50:53 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="2">Quality of evidence</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">Aspirin versus triflusal</HEADING>
<P>The quality of the controlled evidence available to support the use of triflusal for secondary prevention of serious vascular events included five RCTs that we considered suitable for this review. In general, the quality of the included trials was good, as assessed by Jadad's scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Except for the <LINK REF="STD-Matias_x002d_Guiu-1994" TYPE="STUDY">Matias-Guiu 1994</LINK> trial, all trials had adequate allocation concealment. Except for the <LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK> study, all trials used an intention-to-treat analysis. For all included trials we had access to unpublished data and to individual patient data that allowed us to perform several comparisons. We were able to study a total of 5219 patients. However, a significant number of patients in these trials discontinued the study medication early, and permanently, for reasons other than the occurrence of a primary outcome. Although the quality of evidence was considered good for patients with previous ischemic stroke or TIA, we did not have controlled data for patients with disabling stroke or stroke with a probable non-atherothrombotic cause since these patients were excluded from the trials. Only one trial studied patients with AMI in the acute phase (<LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK>). This was a short-term study (35 days) that did not provide evidence for the long-term benefit of triflusal in this type of patient. We found no suitable trials that studied other types of patients at high vascular risk, such as patients with previous myocardial infarction (not acute), coronary heart disease (unstable angina, stable angina, heart failure, coronary angioplasty, coronary artery bypass surgery), high risk of embolism (atrial fibrillation, cardiac valve disease, cardiac valve surgery), peripheral artery disease (intermittent claudication, peripheral grafting, peripheral angioplasty), or other high-risk patients (haemodialysis, diabetes, carotid disease). No conclusions could be made for these types of patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Triflusal versus placebo</HEADING>
<P>Only two trials compared triflusal with placebo for secondary prevention of serious vascular events. Both included a small number of patients with a follow up of six months. The quality of these included trials was good, as assessed by Jadad's scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). One trial included patients with unstable angina and the other included patients with chronic obliterative peripheral arteriopathy. No conclusions could be made for other types of patients. Since there are interventions proved to be of benefit in the secondary prevention of serious vascular events, it is difficult to criticize the scarcity of placebo-controlled data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Methodology</HEADING>
<P>We considered it appropriate to perform a meta-analysis comparing triflusal with aspirin and of triflusal with placebo. Although we tested multiple endpoints, we performed sensitivity analyses that generally showed no differences when trials with poor allocation concealment were excluded. Furthermore, results for all endpoints were consistent with each other. We combined trials that included different types of patients and with different follow-up periods. We performed a subgroup analysis in the triflusal versus aspirin meta-analysis that showed significant differences between stroke or TIA and AMI patients. These differences could be explained by several factors such as different pathologies and different follow-up periods. However, results from these two subgroups were consistent, meaning that they showed the same tendency. This raises the hypothesis that the differences may have been due to the small number of patients included in the AMI subgroup.</P>
<P>Since the <LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK> sequential trial has been handled by means of a standard (fixed sample size) approach using the Peto technique, two issues must be considered with regard to this analysis (<LINK REF="REF-Whitehead-1997" TYPE="REFERENCE">Whitehead 1997</LINK>). First, the 95% CI has a more conservative probability coverage (i.e. greater than 95%), and secondly, the treatment effect estimate is biased in the sense that the treatment estimator, the odds ratio (OR), has been minimised. However, both issues benefit the aspirin arm and, therefore, the present analysis can be regarded as conservative for the potential benefit of triflusal. The <LINK REF="STD-TIM" TYPE="STUDY">TIM</LINK> results for the primary composite outcome, analysed with and without the sequential adjustment, are presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Findings</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">Aspirin versus triflusal</HEADING>
<P>Results did not show a significant difference between aspirin and triflusal for the primary outcome, the effect on serious vascular events. However, the confidence interval was wide and included clinically significant effects in both directions. For secondary efficacy outcomes, statistically significant differences were found for the number of patients with fatal ischemic stroke, any hemorrhagic stroke and non-fatal hemorrhagic stroke where triflusal prevented significantly more events. These differences are probably due to the relatively small number of patients enrolled in the analysis, as suggested by the large numbers needed to treat result.</P>
<P>For safety and tolerability outcomes we found significant differences for the majority of outcomes related with hemorrhagic adverse events, either serious or not. These differences favoured triflusal over aspirin. Since these results were very consistent, producing numbers needed to harm not too large, triflusal probably has a significantly lower hemorrhagic risk for both major and minor hemorrhages. On the other hand, aspirin was associated with fewer non-hemorrhagic gastrointestinal adverse events.<BR/>These trials provided data on the relative effects of triflusal for secondary prevention in patients with a history of previous stroke, TIA or AMI, and did not provide evidence for other categories of patients at high vascular risk. These studies did not use any measures of quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Triflusal versus placebo</HEADING>
<P>We found two small trials comparing triflusal with placebo in patients with unstable angina and chronic obliterative peripheral arteriopathy. Fewer comparisons could be performed between the two interventions compared with those made in the previous meta-analysis. For the primary outcome, triflusal prevented a significantly greater number of serious vascular events than placebo. This was associated with a higher number of non-serious adverse events. No conclusions could be made for secondary prevention in other groups of patients at high vascular risk. It is not reasonable to expect more trials comparing triflusal with placebo since available interventions have proven benefit.</P>
<P>We aimed to study all groups of patients at high vascular risk. However, this review covers only three high-risk groups: ischemic cerebrovascular disease, myocardial infarction, and peripheral arterial disease, since studies with other high-risk groups were not found. Other high-risk patient groups will be included in later updates of this review if such studies are performed.</P>
</SUBSECTION>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This systematic review has not shown a significant difference between aspirin and triflusal for secondary prevention of serious vascular events in patients with a previous non-disabling stroke, TIA or acute myocardial infarction. Furthermore, the confidence intervals are wide and cannot exclude the possibility that triflusal is significantly better than, or significantly worse than, aspirin. Although triflusal was associated with a significantly lower risk of either major or minor hemorrhagic complications it had a higher risk of non-hemorrhagic gastrointestinal complications.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future trials should explore the efficacy and safety of triflusal in other groups of patients who are at high vascular risk and the possible additional benefit of combined antiplatelet therapy for secondary prevention of serious vascular events.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P> We thank Grupo Uriach (Barcelona, Spain) for providing the full results of the trials included.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The authors JM Ferro, J Matias-Guiu, J Alvarez-Sabin, and F Torres were members of the TACIP (Triflusal Aspirin Cerebral Infarction Prevention) Study Steering Committee and received grants from the study sponsor. The author F Torres has also been involved in another trial (TIM study), and is involved in an on-going trial of triflusal in mild cognitive impairment. Although the authors have been closely involved with the trials and have received grants from the company for participation in these studies, the company did not fund any aspect of the review or have any input to the design, analysis or writing of the review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Protocol: Costa J and Ferro JM<BR/>Literature search: Costa J and Ferro JM<BR/>Literature selection: Costa J and Ferro JM<BR/>Papers quality assessment: Costa J and Ferro JM<BR/>Data collection from papers: Costa J and Ferro JM<BR/>Interpretation of data: all authors<BR/>Review writing: all authors</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-08 15:21:13 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2008-10-08 15:21:13 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Auteri-1995" NAME="Auteri 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Auteri A, Angaroni A, Borgatti E, Catalano M, De Vizzi GB, Forconi S, et al</AU>
<TI>Triflusal in the treatment of patients with chronic peripheral arteriopathy: Multicentre double-blind clinical study vs placebo</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>2</NO>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forconi S per il Gruppo de Studio Multicentrico</AU>
<TI>Triflusal in the treatment of patients with chronic peripheral arteriopathy</TI>
<SO>Giornale di Gerontologia</SO>
<YR>1995</YR>
<VL>43</VL>
<PG>571-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-GEAIT" NAME="GEAIT" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Rubira JC, Cruz JM, López V, Plaza L, Navas JC, Grupo de Estudio del Triflusal en la Angina Inestable</AU>
<TI>Outcome of patients with diabetes and unstable angina. A subgroup analysis in the Spanish Multicentre Trial of trifusal in unstable angina</TI>
<SO>International Journal of Cardiology</SO>
<YR>1994</YR>
<VL>46</VL>
<NO>2</NO>
<PG>175-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grupo Español Angina Inestable-Triflusal (GEAIT)</AU>
<TI>Triflusal in the prevention of myocardial infarction in unstable angina: multicentre national study</TI>
<TO>Triflusal en la prevención del infarto de miocardio en la angina inestable: estudio multicéntrico nacional</TO>
<SO>Revista Española de Cardiología</SO>
<YR>1991</YR>
<VL>44 (Suppl 1)</VL>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Plaza L, Lopez-Bescos L, Martin-Jadraque L, Alegria E, Cruz-Fernandez JM, Velasco J, et al</AU>
<TI>Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial</TI>
<SO>Cardiology</SO>
<YR>1993</YR>
<VL>82</VL>
<NO>6</NO>
<PG>388-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Matias_x002d_Guiu-1994" NAME="Matias-Guiu 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Álvarez Sabín J, Matías-Guiu J, Galiano L, Codina Puiggrós A</AU>
<TI>The risk of hemorrhage in long-term use of aspirin and triflusal</TI>
<TO>El riesgo hemorrágico en la toma prolongada de aspirina y triflusal</TO>
<SO>Revista de Neurologia</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>160</NO>
<PG>951-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias Guiu J, Alvarez J, Galiano L, Codina A</AU>
<TI>The efficacy and safety of low-dose aspirin versus triflusal in the long-term outcome of young stroke patients</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44 (Suppl 2)</VL>
<PG>288A (Abstract 636P)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matias Guiu J, Alvarez-Sabin J, Codina A</AU>
<TI>Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease</TI>
<TO>Estudio comparativo del efecto del acido acetilsalisílico en dosis bajas y el triflusal en la prevención de eventos cardiovasculares en adultos jóvenes con enfermedad cerebrovascular isquémica</TO>
<SO>Revista de Neurologia</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>147</NO>
<PG>1669-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias Guiu J, Alvarez-Sabin J, Codina A</AU>
<TI>Comparative study of the effect of low-dose aspirin and triflusal in the prevention of cardiovascular events in young adults with ischaemic cerebrovascular disease</TI>
<TO>Estudio comparativo del efecto del acido acetilsalisílico en dosis bajas y el triflusal en la prevención de eventos cardiovasculares en adultos jóvenes con enfermedad cerebrovascular isquémica</TO>
<SO>Acta Neurológica Colombiana</SO>
<YR>1998</YR>
<VL>14</VL>
<NO>2</NO>
<PG>94-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias Guiu J, Alvarez-Sabin J, Codina A</AU>
<TI>Comparative study of the effect of low-dose aspirin and triflusal in the prevention of cardiovascular events in young adults with ischaemic cerebrovascular disease</TI>
<TO>Estudio comparativo del efecto del acido acetilsalisílico en dosis bajas y el triflusal en la prevención de eventos cardiovasculares en adultos jóvenes con enfermedad cerebrovascular isquémica</TO>
<SO>Revista Ecuatoriana de Neurologia</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>1</NO>
<PG>28-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias-Guiu J, Alverez-Sabin J, Codina A</AU>
<TI>A comparative study of the effects of low doses of acetylsalicyclic acid and triflusal in the prevention of cardiovascular incidents in young adults with ischemic cerebrovascular disease</TI>
<TO>Estudo comparativo dos efeitos de baixas doses de ácido acetilsalicílico e de triflusal na prevenção de acidentes cardiovasculares em jovens adultos com doença cerebrovascular isquémica</TO>
<SO>Revista Brasileira de Neurologia</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>147</NO>
<PG>1669-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Smirne-1994" NAME="Smirne 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smirne S, Ferini-Strambi L, Cicinotta D, Zamboni M, Ambrosoli L, Poli A</AU>
<TI>Triflusal and prevention of cerebrovascular attacks: double blind clinical study vs asa</TI>
<SO>Journal of Neurology</SO>
<YR>1994</YR>
<VL>241</VL>
<NO>1</NO>
<PG>Abstract 53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smirne S</AU>
<TI>Triflusal in the prevention of cerebrovascular attacks</TI>
<TO>Il triflusal nella prevenzione degli accidenti cerebrovasculari</TO>
<SO>Giornale di Gerontologia</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>10</NO>
<PG>563-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-TACIP" NAME="TACIP" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dent NJ</AU>
<TI>Auditing experiences in Spain and Portugal of a multinational, large scale phase IV study</TI>
<SO>Quality Assurance Journal</SO>
<YR>1998</YR>
<VL>3</VL>
<PG>119-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drug Week editors</AU>
<TI>Recurrence risk lower anti-clotting drug than aspirin</TI>
<SO>Drug Week</SO>
<YR>2001</YR>
<VL>March 9</VL>
<PG>14-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias-Guiu J for the TACIP Steering Commitee</AU>
<TI>Triflusal Aspirin Cerebral Infarction Prevention (TACIP) Study</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1996</YR>
<VL>6 (Suppl 2)</VL>
<PG>76-77 (Abstract P388)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias-Guiu J, Ferro JM, Alvarez-Sabin J for the TACIP Steering Commitee</AU>
<TI>Triflusal Aspirin Cerebral Infarction Prevention (TACIP Study). Ongoing Clinical Trial</TI>
<SO>Cerebrovascular Disorders</SO>
<YR>1998</YR>
<VL>8 (Suppl 4)</VL>
<PG>86 (Abstract OCT 22)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Matias-Guiu J, Ferro JM, Alvarez-Sabin J for the TACIP Steering Commitee</AU>
<TI>Triflusal Aspirin Cerebral Infarction Prevention (TACIP Study). Ongoing Clinical Trial</TI>
<SO>22nd International Joint Conference On Stroke And Cerebral Circulation</SO>
<YR>1997</YR>
<PG>Abstract CT10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias-Guiu J, Ferro JM, Alvarez-Sabin J, G Calvo, on behalf of the TACIP Study Group</AU>
<TI>Triflusal versus aspirin in secondary stroke prevention: results of TACIP Study</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>11</NO>
<PG>2868 (Abstract 722)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, et al</AU>
<TI>Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<NO>4</NO>
<PG>840-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F</AU>
<TI>Triflusal versus aspirin in secondary stroke prevention: results of TACIP Study</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>329 (Abstract 73)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Matias-Guiu J</AU>
<TI>Triflusal vs acetylsalicyclic acid in secondary prevention of cerebral infarction - TACIP</TI>
<SO>www.strokecenter.org/trials/list</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>TACIP Study Group</AU>
<TI>Triflusal Aspirin Cerebral Infarction Prevention (TACIP) Study. Ongoing clinical trial</TI>
<SO>Methods And Findings In Experimental And Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>18 (Suppl C)</VL>
<PG>92 (Abstract P-37)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The TACIP Study - Steering Committee</AU>
<TI>TACIP Study: comparison of triflusal and moderate doses of aspirin in prevention of stroke</TI>
<SO>European Journal of Neurology</SO>
<YR>1998</YR>
<VL>5 (Suppl 1)</VL>
<PG>S46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torres F, Rios J, Perez I, Pontes C, Munoz G, Navas C</AU>
<TI>Combined analysis of triflusal in secondary prevention of stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2001</YR>
<VL>11 (Suppl 4)</VL>
<PG>74 (Abstract treat_1)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-TAPIRSS" NAME="TAPIRSS" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, et al</AU>
<TI>Triflusal vs aspirin for prevention of cerebral infarction. A randomized stroke study</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<PG>1073&#8211;80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, et al</AU>
<TI>Triflusal is preferable to aspirin for the secondary prevention of ischemic stroke</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>2001</YR>
<VL>187 (Suppl 1)</VL>
<PG>S123 (Abstract 25.02)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, et al</AU>
<TI>Triflusal vs Aspirin for the Prevention of Infarction: a Randomized Stroke Study (TAPIRSS)</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>377 (Abstract P208)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culebras A, Symecko H for the TAPIRSS Investigators</AU>
<TI>Baseline characteristics of persons enrolled in TAPIRSS</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>1997</YR>
<VL>150 (Suppl)</VL>
<PG>S191 (Abstract 3-36-05)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Culebras A</AU>
<TI>Triflusal vs aspirin for the prevention of infarction: randomized stroke study - TAPIRSS</TI>
<SO>www.strokecenter.org/trials/list</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culebras A</AU>
<TI>Triflusal: an effective antiplatelet agent with significantly lower hemorrhagic risk than ASA</TI>
<SO>Today's Therapeutic Trends</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>4</NO>
<PG>271-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Symecko H, Culebras A</AU>
<TI>Triflusal versus aspirin for the prevention of infarction (TAPIRSS): a randomized stroke study</TI>
<SO>European Journal of Neurology</SO>
<YR>1998</YR>
<VL>5 (Suppl 3)</VL>
<PG>S107-8 (Abstract Mts132)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Symecko HL, Lipset CH, Culebras A</AU>
<TI>Clinical trials in Latin America</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1997</YR>
<VL>7 (Suppl 4)</VL>
<PG>71 (Abstract EPI22)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torres F, Rios J, Perez I, Pontes C, Munoz G, Navas C</AU>
<TI>Combined analysis of triflusal in secondary prevention of stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2001</YR>
<VL>11 (Suppl 4)</VL>
<PG>74 (Abstract treat_1)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-TIM" NAME="TIM" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruz-Fernandez JM, Lopez V, Martin-Jadraque L, Navas C, Cabades A, Calvo G, et al</AU>
<TI>Triflusal vs aspirin in acute myocardial infarction: protocol of study and preliminary data</TI>
<TO>Triflusal vs Aspirina en el infarto agudo de miocardio: protocolo de estudio y datos preliminares</TO>
<SO>Revista Española de Cardiología</SO>
<YR>1993</YR>
<VL>46 (Suppl 1)</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cruz-Fernandez JM, Lopez-Bescos L, Garcia-Dorado D, Lopez Garcia-Aranda V, Cabades A, Martin-Jadraque L, et al</AU>
<TI>Randomized comparative trial of triflusal and aspirin following acute myocardial infarction</TI>
<SO>European Heart Journal</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>6</NO>
<PG>457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Darba J, Izquierdo I, Pontes C, Navas C, Rovira J</AU>
<TI>Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction</TI>
<SO>Pharmacoeconomics</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>3</NO>
<PG>195-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-08 15:21:13 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez_x002d_Sabin-1996" MODIFIED="2008-10-08 15:19:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="Alvarez-Sabin 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-08 15:19:59 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez-Sabin J, Molina C, Martín R, Matias-Guiu J</AU>
<TI>The tolerance of two therapeutic uses of triflusal in patients with ischemic stroke and triflusal</TI>
<TO>Tolerancia de dos pautas de tratamiento de triflusal en pacientes con ictus isquémico</TO>
<SO>Revista de Neurologia</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>134</NO>
<PG>1306-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arcas-1981" MODIFIED="2008-10-08 15:20:03 +0100" MODIFIED_BY="Hazel Fraser" NAME="Arcas 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-10-08 15:20:03 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arcas R, Herreros J, Rocha E, Horonato J, Azanza Perea J</AU>
<TI>Clinico-biological effectiveness of triflusal during the postoperative period of patients with chronic ischemic syndrome of the extremities</TI>
<TO>Estudio de la eficacia clínico-biológica de triflusal en el postoperatorio de pacientes afectos de síndrome isquémico crónico de las extremidades</TO>
<SO>Revista de Medicina de la Universidad de Navarra</SO>
<YR>1981</YR>
<VL>25</VL>
<NO>2</NO>
<PG>51-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bescos-1999" MODIFIED="2008-10-08 15:20:07 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bescos 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-08 15:20:07 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Bescos L, Calades O'Callaghan A, Castro-Beiras A, Kallmeyer Martin A, Martin-Jadraque L, Garcia-Dorado D, et al</AU>
<TI>Incidence of vascular stroke in patients with acute myocardial infarction receiving fibrinolytic treatment</TI>
<SO>European Heart Journal Supplements</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>F</NO>
<PG>F19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-1999" MODIFIED="2008-10-08 15:20:11 +0100" MODIFIED_BY="Hazel Fraser" NAME="Cesarone 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-08 15:20:11 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Laurora G, DeSanctis MT, Incandela L, Fugazza L, Girardello R, et al</AU>
<TI>Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound</TI>
<SO>Angiology</SO>
<YR>1999</YR>
<VL>50</VL>
<NO>6</NO>
<PG>455-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-la-Torre-1984" MODIFIED="2008-10-08 15:20:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="De la Torre 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-10-08 15:20:14 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De la Torre AG, Pacho J, Estevan JM, Valle A, Olay JR, Diez O, et al</AU>
<TI>Long-term clinical and biological study of a thrombocyte antiaggregant (Triflusal) in patients with progressive atherosclerosis</TI>
<TO>Estudio clinico-biologico a largo plazo de un antiagregante plaquetario (Triflusal) en pacientes con arteriosclerosis evolutiva</TO>
<SO>Angiologia (Spain)</SO>
<YR>1984</YR>
<VL>36</VL>
<NO>6</NO>
<PG>279-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garay-Lillo-1987" MODIFIED="2008-10-08 15:20:17 +0100" MODIFIED_BY="Hazel Fraser" NAME="Garay Lillo 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-10-08 15:20:17 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garay Lillo J, Florez Tascon FJ, Roca Roca F, Martinez Manzanares C, Caballero Garcia JC, Guijarro Garcia JL, et al</AU>
<TI>Multicenter clinical study on acceptability of triflusal in prevention of cerebral vascular accident</TI>
<TO>ETPA: Estudio clínico multicéntrico para valorar la tolerancia de Triflusal en la prevención del accidente vascular cerebral</TO>
<SO>Geriatrika (Spain)</SO>
<YR>1987</YR>
<VL>3</VL>
<NO>4</NO>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guiteras-1989" MODIFIED="2008-10-08 15:20:23 +0100" MODIFIED_BY="Hazel Fraser" NAME="Guiteras 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-10-08 15:20:23 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guiteras P, Altimiras J, Aris A, Auge JM, Bassons T, Bonal J, et al</AU>
<TI>Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: A randomized, double-blind, placebo-controlled trial</TI>
<SO>European Heart Journal</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>2</NO>
<PG>159-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kwon-1996" MODIFIED="2008-10-08 15:20:31 +0100" MODIFIED_BY="Hazel Fraser" NAME="Kwon 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-08 15:20:31 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kwon SU, Ahn JY, Yun BW, Park SS, Roh JK</AU>
<TI>A clinical trial on the safety and the inhibitory effect of platelet aggregation by triflusal (Disgren(TM)) in the patients with cerebral thrombosis</TI>
<SO>Journal of Korean Society for Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>1</NO>
<PG>20-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanas-2003" MODIFIED="2008-10-08 15:20:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="Lanas 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-08 15:20:35 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R</AU>
<TI>Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>2</NO>
<PG>173-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masotti-1991" MODIFIED="2008-10-08 15:20:39 +0100" MODIFIED_BY="Hazel Fraser" NAME="Masotti 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-10-08 15:20:39 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masotti M, Tura A, Crexells C, Oriol A</AU>
<TI>Antiplatelet agents and their effect on complications during or soon after percutaneous transluminal coronary angioplasty</TI>
<SO>Journal of International Medical Research</SO>
<YR>1991</YR>
<VL>19</VL>
<NO>5</NO>
<PG>414-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monreal-1995" MODIFIED="2008-10-08 15:20:42 +0100" MODIFIED_BY="Hazel Fraser" NAME="Monreal 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-10-08 15:20:42 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monreal M, Lafoz E, Roca J, Granero X, Soler J, Salazar X, et al</AU>
<TI>Platelet count, antiplatelet therapy and pulmonary embolism - A prospective study in patients with hip surgery</TI>
<SO>Thrombosis &amp; Haemostasis</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>3</NO>
<PG>380-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NASPEAF-2004" MODIFIED="2008-10-08 15:20:46 +0100" MODIFIED_BY="Hazel Fraser" NAME="NASPEAF 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-08 15:20:46 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Pérez-Gómez F, Alegría E, Berjón J, A Iriarte J, Zumalde J, Salvador A, et al</AU>
<TI>Comparative effects of antiplatelet, anticoagulant or combined therapy in patients with valvular and non-valvular atrial fibrillation. A randomised multi-centre study</TI>
<SO>Journal of the American College of Cardiology (accepted for publication)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez-2002" MODIFIED="2008-10-08 15:20:58 +0100" MODIFIED_BY="Hazel Fraser" NAME="Perez 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-08 15:20:58 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez Gomez F, Lourenzo PI, Companion J, Escriba A, Perez Saldana D, Guillen M, et al</AU>
<TI>Platelet aggregation in different antithrombotic regimens. Possible proaggregant effect of low level oral anticoagulation</TI>
<TO>Antiagregação plaquetária em diferentes regimes antitrombótcos. Possível efeito proagregante de anticoagulação oral de baixo valor</TO>
<SO>Revista Portuguesa de Cardiologia</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>5</NO>
<PG>541-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pontes-2001" MODIFIED="2008-10-08 15:21:01 +0100" MODIFIED_BY="Hazel Fraser" NAME="Pontes 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-08 15:21:01 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pontes C, Perez I, Rios J, Izquierdo I, Navas JC, Matias-Guiu J, et al</AU>
<TI>Aspirin but not triflusal increased antihypertensive therapy requirements during long term antiplatelet treatment</TI>
<SO>Pharmacology and Toxicology</SO>
<YR>2001</YR>
<VL>89 (Suppl 1)</VL>
<PG>79 (Abstract 304)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Putz-1991" MODIFIED="2008-10-08 15:21:05 +0100" MODIFIED_BY="Hazel Fraser" NAME="Putz 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-10-08 15:21:05 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Putz P, Buyse H, Delvaux D, Kutnowski M, Demulder A, Dumont N, et al</AU>
<TI>Triflusal versus acetylsalicylic acid: a double-blind study for the prophylaxis of deep vein thrombosis after hip surgery</TI>
<SO>Acta Chirurgica Belgica</SO>
<YR>1991</YR>
<VL>91</VL>
<NO>6</NO>
<PG>269-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sala_x002d_Planell-1981" MODIFIED="2008-10-08 15:21:08 +0100" MODIFIED_BY="Hazel Fraser" NAME="Sala-Planell 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-10-08 15:21:08 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sala-Planell E, La Torre J, Marinel-Lo J, Rutllant ML, Miralles J, Ramirez de Avellano R</AU>
<TI>Clinical and biologic evaluation of triflusal in arteriosclerotic patients with high risk of thrombosis. Long-term study</TI>
<TO>Valoración clínico-biológica del efecto del Triflusal en pacientes arterioscleróticos de alto riesgo trombótico. Estudio a largo plazo.</TO>
<SO>Angiologia (Spain)</SO>
<YR>1981</YR>
<VL>33</VL>
<NO>2</NO>
<PG>71-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zan-2002" MODIFIED="2008-10-08 15:21:13 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zan 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-08 15:21:13 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zan S, Maselli M, Moniaci D, Varetto G, Ortensio M, Apostolou D, et al</AU>
<TI>Compliance of geriatric patients subjected to antiplatelet agents with Triflusal in peripheral arteriopathy. Preliminary data</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>3</NO>
<PG>263-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Altman-2002" NAME="Altman 2002" TYPE="OTHER">
<AU>Altman DG, Deeks JJ</AU>
<TI>Meta-analysis, Simpson's paradox, and the number needed to treat</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>1</NO>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APT" NAME="APT" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists' Collaboration</AU>
<TI>Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<NO>6923</NO>
<PG>235-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATC" NAME="ATC" TYPE="JOURNAL_ARTICLE">
<AU>Antithrombotic Trialists' Collaboration</AU>
<TI>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>324</VL>
<PG>71-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bamford-1990" NAME="Bamford 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bamford J, Sandercock P, Dennis M, Burn J, Warlow C</AU>
<TI>A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project - 1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1990</YR>
<VL>53</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CAPRIE" NAME="CAPRIE" TYPE="JOURNAL_ARTICLE">
<AU>CAPRIE Steering Committee</AU>
<TI>A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9038</NO>
<PG>1329-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cruz_x002d_Fernandez-2000" NAME="Cruz-Fernandez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cruz-Fernandez JM, Lopez-Bescos L, Garcia-Dorado D, Lopez García-Aranda V, Cabades A, Martín-Jadraque L, et al</AU>
<TI>Randomized comparative trial of triflusal and aspirin following acute myocardial infarction</TI>
<SO>European Heart Journal</SO>
<YR>2000</YR>
<VL>21</VL>
<PG>457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-la-Cruz-1988" NAME="De la Cruz 1988" TYPE="JOURNAL_ARTICLE">
<AU>De La Cruz JP, Pavia J, Garcia-Arnes J, Sanchez de la Cuesta F</AU>
<TI>Effects of triflusal and acetylsalycilic acid on platelet aggregation in whole blood of diabetic patients</TI>
<SO>European Journal of Haematology</SO>
<YR>1988</YR>
<VL>40</VL>
<PG>232-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-la-Cruz-1995" NAME="De la Cruz 1995" TYPE="JOURNAL_ARTICLE">
<AU>De la Cruz JP, Villalobos MA, García PJ, Smith-Agreda JM, Sánchez de la Cuesta F</AU>
<TI>Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>47</VL>
<PG>497-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>Systematic Reviews in health Care: Meta-Analysis in context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publication Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Diener-1996" NAME="Diener 1996" TYPE="JOURNAL_ARTICLE">
<AU>Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A</AU>
<TI>European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>1996</YR>
<VL>143</VL>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fernandez-1999" NAME="Fernandez 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez de Arriba A, Cavalcanti F, Miralles A, Bayon Y, Alonso A, Merlos M, et al</AU>
<TI>Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid</TI>
<SO>Molecular Pharmacology</SO>
<YR>1999</YR>
<VL>55</VL>
<PG>753-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garc_x00ed_a-1986" NAME="García 1986" TYPE="JOURNAL_ARTICLE">
<AU>García-Rafanell J, Ramis J, Gómez L, Forn J</AU>
<TI>Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets</TI>
<SO>Archives Internationales de Pharmacodynamie et de Thérapie</SO>
<YR>1986</YR>
<VL>284</VL>
<PG>155-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hankey-2000" NAME="Hankey 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hankey GJ, Sudlow CL, Dunbabin DW</AU>
<TI>Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>1779-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matias_x002d_Guiu-1997" NAME="Matias-Guiu 1997" TYPE="JOURNAL_ARTICLE">
<AU>Matias-Guiu J, Alvarez-Sabin J, Codina A</AU>
<TI>Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease</TI>
<SO>Revista de Neurologia</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>1669-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matias_x002d_Guiu-2001" NAME="Matias-Guiu 2001" TYPE="JOURNAL_ARTICLE">
<AU>Matías-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F</AU>
<TI>Triflusal versus aspirin in secondary stroke prevention: results of TACIP study</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>329b</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plaza-1993" NAME="Plaza 1993" TYPE="JOURNAL_ARTICLE">
<AU>Plaza L, Lopez-Bescos L, Martin-Jadraque L, Alegria E, Cruz-Fernández JM, Velasco J, et al</AU>
<TI>Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Grupo de Estudio del Triflusal en la Angina Inestable</TI>
<SO>Cardiology</SO>
<YR>1993</YR>
<VL>82</VL>
<PG>388-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanchez-2000" NAME="Sanchez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez de Miguel L, Jimenez A, Monton M, Farre J, Arriero M, Rodriguez-Feo JA, et al</AU>
<TI>A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>811-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smeeth-1999" NAME="Smeeth 1999" TYPE="JOURNAL_ARTICLE">
<AU>Smeeth L, Haines A, Ebrahim S</AU>
<TI>Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<NO>7197</NO>
<PG>1548-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehead-1997" NAME="Whitehead 1997" TYPE="BOOK_SECTION">
<AU>Whitehead J</AU>
<TI>The bias adjusted maximum likelihood estimate</TI>
<SO>The design and analysis of sequential clinical trials</SO>
<YR>1997</YR>
<PG>157-9</PG>
<EN>Revised 2nd edition</EN>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Auteri-1995">
<CHAR_METHODS>
<P>Randomised, multicentre, double-blind, placebo-controlled, 2 arm, parallel study.<BR/>Method of randomisation: random list created by computer.<BR/>Data analysed on a per-protocol basis.<BR/>Location: 7 centres in Italy.<BR/>Duration: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>122 patients were enrolled.<BR/>Triflusal arm: 59 patients; 83% were male; mean age: 61.7±7.2 years; ethnicity: not mentioned; history of smoking habits (41%), hypertension (22%), dyslipidemia (23%), diabetes mellitus (4%), obesity (5%), alcohol consumption (30%), hyperuricemia (6%), and family history (29%).<BR/>There were 4 withdrawals, 1 related to side effects and 3 for other reasons.<BR/>Placebo arm: 63 patients; 90% were male; mean age: 58.5±8.4 years; ethnicity: not mentioned; history of smoking habits (37%), hypertension (16%), dyslipidemia (21%), diabetes mellitus (6%), obesity (4%), alcohol consumption (21%), hyperuricemia (4%), and family history (34%).<BR/>There was 1 withdrawal related to side effects.<BR/>Inclusion criteria: patients with chronic obliterative peripheral arteriopathy (stage II Lériche-Fontaine) whose disease had been stable for a period of time.<BR/>Exclusion criteria: contraindication to salicylate treatment (active ulcer, intolerance or allergy to salicylates, haematological disorders); concomitant treatment with drugs influencing coagulation and fibrinolysis; recent cranial trauma, AMI, or stroke; neoplasm; uncontrolled hypertension; diabetes type 1; peptic ulcers or active organic dyspeptic syndromes; pulmonary, renal, liver, neurological, psychiatric, haematological, and other clinically relevant disorders; surgery in the previous 3 months; and use of narcotics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The study drugs were provided by Poli Industria Chimica S.p.A.. Each patient was randomly assigned to one of the 2 groups: identical uncoated capsules of triflusal (600 mg/d) or placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome event was the estimation of total walking distance using effort tests on the treadmill.<BR/>Secondary outcomes were estimation of pain-free walking distance (treadmill), Winsor index (Strandness test), plethysmography (rest-flow, peak-flow, recovery time, ratio peak-flow/rest-flow, and total time of hyperaemia), clinical signs and symptoms, compliance, and adverse events.<BR/>All outcome data were recorded at baseline and weeks 4, 12, and 24.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-GEAIT">
<CHAR_METHODS>
<P>Randomised, multicentre, double-blind, placebo-controlled, 2 arm, parallel study.<BR/>Method of randomisation: independent centre.<BR/>Data analysed on an intention-to-treat basis.<BR/>Location: 10 centres in Spain.<BR/>Duration: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>281 patients were enrolled.<BR/>Triflusal arm: 143 patients; 83.2% were male; mean age: 58.4±7.8 years; ethnicity: not mentioned; history of smoking habits (56.5%), hypertension (25.5%), dyslipidemia (25%), diabetes mellitus (20.6%), obesity (25.9%), angina pectoris (69.7%), MI (40.1%), peripheral arteriopathy (12.1%), and aortocoronary bypass surgery (4.2%). The qualifying event unstable angina was recent in 35.7%, progressive in 13.3%, prolonged in 22.4%, and at rest in 35%. Concomitant conventional therapy used included calcium antagonists (84.2%), nitrates (69.2%), beta-blockers (37%), diuretics (12.4%), and other antihypertensive drugs (8.1%). There were 15 withdrawals related to side effects (7), protocol violation (1), patient refusal (2), non-compliance (1), general surgery (2), and other reasons (2).<BR/>Placebo arm: 138 patients; 75.4% were male; mean age: 59.3±6.7 years; ethnicity: not mentioned; history of: smoking habits (67.8%), hypertension (40.6%), dyslipidemia (19.6%), diabetes mellitus (21.5%), obesity (20.5%), angina pectoris (63.8%), MI (37.2%), peripheral arteriopathy (12.4%), and aortocoronary bypass surgery (4.4%). The qualifying event unstable angina was recent in 32.6%, progressive in 17.4%, prolonged in 29.7%, and at rest in 37%. Concomitant conventional therapy used included calcium antagonists (93.7%), nitrates (73.5%), beta-blockers (41.6%), diuretics (6.5%), and other antihypertensive drugs (7.9%). There were 16 withdrawals related to side effects (6), protocol violation (2), patient refusal (1), non-compliance (2), randomisation error (3), and concurrent disease (2).<BR/>Inclusion criteria: age &lt; 70 years; unstable angina admitted to a coronary unit; informed consent.<BR/>Exclusion criteria: AMI in progress or in the previous 6 weeks (excluded by negative ECG and negative enzyme criteria and 99mTc pyrophosphate scintigraphy); antiplatelet agents (aspirin) still given during the previous 7 days; angiographic evaluations during the previous 7 days; diastolic blood pressure &gt; 115 mmHg; anticoagulant or fibrinolytic treatment; aortocoronary bypass in the previous 12 weeks; contraindication to salicylate treatment (active ulcer during the previous 3 months, intolerance or allergy to salicylates, haematological disorders); possible low patient compliance; Prinzmetal's angina; congestive heart failure (NYHA class IV); tachyarrhythmia (ventricular rate &gt; 150 bpm); anemia (Hb &lt; 10 g/dl); concomitant illness with a life expectancy of less than 1 year; thyrotoxicosis; hypotension (systolic blood pressure &lt; 90 mmHg); fever (= 39ºC); and pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The study drugs were provided by Grupo Uriach, Barcelona, Spain. Each patient was randomly assigned to one of the 2 groups: identical uncoated capsules of triflusal (900 mg/d) or placebo. The randomisation occurred 48 to 72 h after admission. On admission all patients received standard treatment (beta-blockers, nitrates or calcium antagonists).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome event was a composite outcome and included the first occurrence of cardiac death (death occurring within 1 month of an acute episode of pain or reinfarction, or when the results of autopsy proved that death had been caused by AMI), vascular death (any death related to: stroke, heart failure, and sudden death), or non-fatal AMI (either Q-wave MI defined as the presence of a new Q-wave according to the Minnesota Code and confirmed by gradual changes in enzymes and chest pain, or non-Q-wave MI defined as an increase in cardiac enzymes to at least twice the normal upper limits, usually with prolonged chest pain and new S-T changes).<BR/>Secondary outcomes were the necessity for myocardial revascularisation, treatment compliance, and adverse events (assessed by closed and open questionnaire).<BR/>All outcome data were recorded at baseline and weeks 2, 4, 8, 12, and 24.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unstable angina was defined as: (1) effort angina of recent onset or progression of angina diagnosed as stable in the preceding month, plus one of the following criteria: (a) previous MI; (b) S-T segment depression = 0.1mv at 0.08s from the J point during one of the pain episodes; (c) coronary angiography showing 1 or more significant coronary stenoses (= 75% cross-sectional diameter), or (d) positive stress or thallium stress-testing showing S-T segment depression. (2) angina at rest with transitory S-T segmental alterations.<BR/>With the exception of hematocrit that was higher in the triflusal group (44.7±3.7 vs 43.4±3.9), all clinical (blood pressure, heart rate), laboratory (haemoglobin, cholesterol, triglycerides, cardiac enzymes), and ECG parameters (Q-wave, S-T segment elevation) were not statistically different between groups at baseline.<BR/>Concerning baseline characteristics, there were 2 significant differences between groups (history of hypertension and concomitant use of calcium antagonists).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Matias_x002d_Guiu-1994">
<CHAR_METHODS>
<P>Quasi-randomised, aspirin-controlled, 2 arm, parallel study.<BR/>Method of randomisation: allocation by alternative days.<BR/>Data analysed on an intention-to-treat basis.<BR/>Location: 2 centres in Spain.<BR/>Duration: mean of 47.3±16.5 months (range: 3 to 94).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>217 patients were enrolled.<BR/>Triflusal arm: 106 patients; 79% were male; mean age: 42.7 years; ethnicity: not mentioned; previous history of hypertension (28.3%), diabetes mellitus (20.8%), dyslipidemia (59.4%), smoking habits (64.2%), alcohol consumption (47.2%). Hematocrit &gt; 50 in 23.6%. Extracranial stenosis &gt; 70% in 38.7% of the patients.<BR/>Percentage of patients with previous history of: hemorrhagic stroke (0%), angina pectoris (1.9%), myocardial infarction (1.9%), peripheral arteriopathy (10.4%), and arterial surgery (1.9%).<BR/>The qualifying event was ischemic stroke (first event) in all patients. The vascular territory was cortical in 60.4%, lacunar in 18.9%, and brainstem in 20.7 %.<BR/>Previous treatment with antiplatelets (14.2%) or anticoagulants (0%).<BR/>Aspirin arm: 111 patients; 82% were male; mean age: 43.2 years; ethnicity: not mentioned; previous history of hypertension (33.3%), diabetes mellitus (16.2%), dyslipidemia (60.4%), smoking habits (64%), alcohol consumption (3.8%). Hematocrit &gt; 50 in 18%. Extracranial stenosis &gt; 70% in 25.2% of the patients.<BR/>Percentage of patients with previous history of: hemorrhagic stroke (0%), angina pectoris (2.7%), myocardial infarction (2.7%), peripheral arteriopathy (9%), and arterial surgery (0.9%).<BR/>The qualifying event was ischemic stroke (first event) in all patients. The vascular territory was cortical in 64.9%, lacunar in 18%, and brainstem in 17.1%.<BR/>Previous treatment with antiplatelets (12.6%) or anticoagulants (0%).<BR/>Inclusion criteria: age &lt; 50 years; cerebral infarction of probable atherothrombotic cause (first-event); brain CT scan and/or MRI studies; informed consent. TIA was not an inclusion criteria.<BR/>Exclusion criteria: evidence of intracerebral hemorrhage; diagnosis of a non-atherothrombotic cause of stroke; history of endarterectomy or indication of this procedure after the qualifying cerebrovascular event; known hypersensitivity to salicylates; need for antiplatelet therapy; active peptic ulcer or history of upper gastrointestinal bleeding; liver or renal dysfunction; severe concomitant medical conditions; malignancy that may potentially increase the risk of hemorrhage; and chronic disorders requiring long term treatment with systemic NSAIDs, anticoagulants, or antiplatelet agents.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The study drugs were provided by Grupo Uriach, Barcelona, Spain. Each patient was randomly assigned to 1 of the 2 groups: triflusal (900 mg/d) or aspirin (330 mg/d).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome event was a composite outcome and included the first occurrence of cardiovascular death (any death related to: AMI, ischemic stroke, heart failure, cerebral hemorrhage, unspecified stroke, any systemic thromboembolic episode, rupture of dissecting aneurysm of aorta, and sudden death), non-fatal ischemic stroke (any neurological deficit which appeared after the qualifying event, which lasts more than 24 hours, and without evidence of brain hemorrhage in the head CT), or non-fatal ischemic coronary heart disease (angina pectoris either stable or unstable, or AMI requiring at least 2 of the following criteria: chest pain, ECG criterion, and enzymatic criterion).<BR/>Secondary outcomes were the occurrence of each of these events separately as well as overall mortality. Adverse events data were collected by questionnaire.<BR/>All outcome data were recorded every 3 months.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The trial had poor allocation concealment and was open label.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smirne-1994">
<CHAR_METHODS>
<P>Randomised, multicentre, double-blind, double-dummy aspirin-controlled, 2 arms, parallel study.<BR/>Method of randomisation: randomisation list.<BR/>Data analysed on a per-protocol (efficacy) and on an intention-to-treat basis (safety).<BR/>Location: 13 centres in Italy.<BR/>Duration: 24 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>183 patients were enrolled.<BR/>Triflusal arm: 90 patients; 58.9% were male; mean age: 65.1±9.1 (46-80) years; ethnicity: not mentioned; history of hypertension (53%), diabetes (9%), obesity (9%), dyslipidemia (29%), hyperuricemia (2%), peripheral arteriopathy (5%), alcohol consumption (33%), smoking habits (38%), MI (2%), and ischemia family history (20%). Regarding the qualifying event 78% and 27% of the patients had at least one TIA or RIND, respectively. The cerebral vessels involved were carotids in 67% and vertebro-basilar in 29% of the patients. The time of the last attack was less than 2 weeks in 32%, between 2 and 4 weeks in 28%, and between 4 and 12 weeks in 40%.<BR/>There were 9 withdrawals related to: side effects (3), adverse events (2), treatment refusal (2), lost to follow up (1), and other (1).<BR/>Aspirin arm: 93 patients; 57% were male; mean age: 67.1±9.4 (45-80) years; ethnicity: not mentioned; history of hyperrtension (49%), diabetes (10%), obesity (9%), dyslipidemia (29%), hyperuricemia (0%), peripheral arteriopathy (9%), alcohol consumption (21%), smoking habits (36%), MI (2%), and ischemia family history (22%). Regarding the qualifying event 74% and 30% of the patients had at least one TIA or RIND, respectively. The cerebral vessels involved were carotids in 72% and vertebro-basilar in 19% of the patients. The time of the last attack was less than 2 weeks in 34%, between 2 and 4 weeks in 27%, and between 4 and 12 weeks in 39%.<BR/>There were 9 withdrawals related to: side effects (2), adverse events (1), treatment refusal (4), and lost to follow up (2).<BR/>Inclusion criteria: At least one episode of TIA or RIND in the previous 3 months; no surgical indication; Exclusion of other cerebral disease by CT scan or MRI; informed consent.<BR/>Exclusion criteria: Not compliant; severe neurological deficits (Mathew Scale = 80) or chronic neurological disease; evidence of a possible non-atherothrombotic cause for TIA/RIND; AMI in the previous 3 months; contraindication to salicylate treatment (active ulcer, intolerance or allergy to salicylates, haematological disorders); concomitant treatment with drugs influencing coagulation and fibrinolysis; recent cerebral injury; neoplasm; dementia; uncontrolled hypertension; uncompensated diabetes type 2; diabetes type 1; chronic alcoholism; body mass index &gt; 29; pulmonary, renal, liver, psychiatric, and other clinically relevant disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The study drugs were provided by Poli Industria Chimica S.p.A.. Each patient was randomly assigned to one of the 2 groups: identical uncoated capsules of triflusal (600 mg/d) or aspirin (300 mg/d).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome event was a composite outcome related to prevention of RIA, stroke and vascular death.<BR/>Secondary outcomes: echotomography and Doppler-sonography of extracranial arteries. Adverse events.<BR/>Primary outcome was assessed every 4 weeks. Secondary efficacy outcomes were assessed before and at the end of the treatment (week 24).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TACIP">
<CHAR_METHODS>
<P>Randomised, multicentre, double-blind, aspirin-controlled, 2 arm, parallel, phase III study.<BR/>Method of randomisation: random list generated by an independent centre.<BR/>Data analysed on an intention-to-treat and per-protocol basis.<BR/>Location: 43 centres in Portugal and Spain.<BR/>Duration: 3 years (minimum of 1 year).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>2113 patients were enrolled. 6 patients (3 in each arm) did not take any study medication and were excluded.<BR/>Triflusal arm: 1055 patients (for per-protocol analysis 1018 patients were considered because 25 patients missed 4 or more follow-up visits and 12 patients violated eligibility criteria; study medication was discontinued early and permanently for reasons other than primary event or death in 306 patients); 65.6% were male; mean age: 64.5±9.8 years; ethnicity: 99.3% were caucasian; Mean BMI: 27.2±3.7; active smoking habits: 31.7%; previous history of hypertension (60.9%), dyslipidemia (37.7%), hyperuricemia (11.8%), diabetes mellitus (24.1%), ischemic stroke (9.5%), TIA (12.5%), hemorrhagic stroke (0.7%), angina pectoris (4%), MI (2.1%), peripheral arteriopathy (3.9%), and arterial surgery (1%); mean time to inclusion: 60.2±49 days; the qualifying event was ischemic stroke in 74.7% and TIA in 25.4%: the vascular territory was cortical in 36.3%, lacunar in 50.1%, and brainstem in 13.6%; Oxford score (no symptoms: 39.3%, minor symptoms: 42.3%, and some limitation: 18.4%); previous treatment with antiplatelets (92.5%) or anticoagulants (1.9%).<BR/>Aspirin arm: 1052 patients (for per-protocol analysis 1007 patients were considered because 20 patients missed 4 or more follow-up visits and 25 patients violated eligibility criteria; study medication was discontinued early and permanently for reasons other than primary event or death in 284 patients); 66% were male; mean age: 64.4±9.5 years; ethnicity: 99.1% were caucasian; Mean BMI: 27.4±4; active smoking habits: 30.6%; previous history of hypertension (62.2%), dyslipidemia (39.6%), hyperuricemia (12.6%), diabetes mellitus (24.1%), ischemic stroke (8.7%), TIA (14.5%), hemorrhagic stroke (0.6%), angina pectoris (4.5%), MI (1.7%), peripheral arteriopathy (3.3%), and arterial surgery (0.9%); mean time to inclusion: 60.7±51.1 days; the qualifying event was ischemic stroke in 73.1% and TIA in 26.8%: the vascular territory was cortical in 33.5%, lacunar in 54.1%, and brainstem in 12.5%; Oxford score (no symptoms: 42%, minor symptoms: 41.3%, and some limitation: 16.7%); previous treatment with antiplatelets (93.4%) or anticoagulants (2.2%).<BR/>Inclusion criteria: age older than 39 years; TIA or non-disabling stroke (Oxford Neurological Scale score less than or equal to 2) within the previous 6 months; brain CT scan and/or MRI studies; informed consent.<BR/>Exclusion criteria: evidence of intracerebral hemorrhage; diagnosis of a non-atherothrombotic cause of stroke; history of endarterectomy or indication of this procedure after the qualifying cerebrovascular event; known hypersensitivity to salicylates; need for antiplatelet therapy because of previous ischemic heart disease; active peptic ulcer or history of upper gastrointestinal bleeding; liver or renal dysfunction; severe concomitant medical conditions; malignancy that may potentially increase the risk of hemorrhage; and chronic disorders requiring long-term treatment with systemic NSAIDs, anticoagulants, or antiplatelet agents (anticoagulant or antiplatelet therapy until inclusion was not considered an exclusion criterion, only if the aim of the treatment was the vascular brain disease).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The study drugs were provided by Grupo Uriach, Barcelona, Spain. Each patient was randomly assigned to one of the 2 groups: uncoated capsules of triflusal (600 mg/d) or aspirin (325 mg/d).<BR/>Treatment with any anticoagulant or antiplatelet agent other than the study drug was allowed only for periods not exceeding 7 days per year of patient inclusion in the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome event was a composite outcome and included the first occurrence of vascular death (any death related to: AMI, ischemic stroke, heart failure, cerebral hemorrhage, unspecified stroke, any systemic thromboembolic episode, rupture of dissecting aneurysm of aorta, and sudden death), non-fatal ischemic stroke (any neurological deficit appeared after the qualifying event, which lasts more than 24 h, and without evidence of brain hemorrhage in the head CT), or non-fatal AMI (requiring at least 2 of the following criteria: chest pain, ECG criterion, and enzymatic criterion).<BR/>Secondary outcomes were the occurrence of each of these events separately as well as overall mortality, non-vascular death, non-fatal ischemic stroke, any (fatal and non-fatal) ischemic stroke, non-fatal AMI, any AMI, non-fatal cerebral hemorrhage, any cerebral hemorrhage, major systemic hemorrhage (bleeding episode that required hospital admission and/or blood transfusion; any other bleeding was considered minor), any cerebral and major systemic hemorrhage, non-fatal systemic thromboembolism, and any systemic thromboembolism. Any event that led to death within 1 month of its occurrence was considered a fatal event. Adverse event data were collected by questionnaire and open question.<BR/>All outcome data were recorded at days 30 and 90 after inclusion and at 3-month intervals thereafter until month 36.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All patients were followed until completion of the planned 3-year follow-up period even after the onset of a non-fatal primary end point (off medication) or therapy withdrawal.<BR/>The mean follow up was 30.1 months based on the intention-to-treat analysis.<BR/>Reasons for study drug discontinuation were similar in both groups and included non-serious adverse event (9.1%), patient's willingness (8.7%), or serious adverse event (5.9%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TAPIRSS">
<CHAR_METHODS>
<P>Randomised, multicentre, double-blind, aspirin-controlled, 2 arm, parallel, phase III study.<BR/>Method of randomisation: random list generated by an independent centre.<BR/>Data analysed on an intention-to-treat basis.<BR/>Location: 19 centres in Buenos Aires.<BR/>Duration: minimum of 1 year; maximum of 2 years.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>431 patients were enrolled. 1 patient (triflusal arm) did not take any study medication and was excluded.<BR/>Triflusal arm: 214 patients (1 patient was a violation of eligibility criteria and was excluded from the intention to treat analysis, but included in the safety analysis); 68.5% were male; mean age: 64.2±9.7 years; ethnicity: 88.4% were caucasian; history of smoking habits (26.5%), hypertension (70.7%), dyslipidemia (37.7%), diabetes mellitus (18.6%), ischemic stroke (11.6%), TIA (14%), hemorrhagic stroke (0%), angina pectoris (6.1%), AMI (5.1%), peripheral arteriopathy (3.3%), and vascular surgery (4.2%). The qualifying event was ischemic stroke in 80.3% and TIA in 19.7%. The neuroimaging studies showed a non-lacunar stroke in 36.6%, lacunar stroke in 39.4%, old non-lacunar stroke in 10.3%, and old lacunar stroke in 37.6%. Previous treatment with antiplatelets (81.4%) or anticoagulants (1.4%).<BR/>Aspirin arm: 216 patients; 68.1% were male; mean age: 65.2±10.1 years; ethnicity: 90.7% were caucasian; history of: smoking habits (27.8%), hypertension (69.9%), dyslipidemia (36.6%), diabetes mellitus (17.6%), ischemic stroke (13.9%), TIA (17.1%), hemorrhagic stroke (0.5%), angina pectoris (6.5%), AMI (6%), peripheral arteriopathy (3.7%), and vascular surgery (2.8%). The qualifying event was ischemic stroke in 81.5% and TIA in 18.5%. The neuroimaging studies showed a non-lacunar stroke in 39.4%, lacunar stroke in 43.1%, old non-lacunar stroke in 4.6%, and old lacunar stroke in 40.7%. Previous treatment with antiplatelets (81.9%) or anticoagulants (0.9%).<BR/>Inclusion criteria: Age older than 39 years; TIA or non-disabling stroke (Oxford Neurological Scale score less than or equal to 2) within the previous 6 months; brain CT scan and/or MRI studies; informed consent.<BR/>Exclusion criteria: cerebral hemorrhage; stroke of non-atherothrombotic cause; history of endarterectomy; cardiogenic emboli (prosthetic valve, atrial fibrillation); recent AMI (&lt; 4 months of evolution); renal insufficiency, liver failure, HIV infection, or heart failure grade III-V; life expectancy &lt; 2 years; active peptic ulcer; pregnancy and breast-feeding; need of chronic treatment with systemic NSAIDs, anticoagulants, or antiplatelet agents (anticoagulant or antiplatelet therapy until inclusion was not considered an exclusion criterion, only if the aim of the treatment was the vascular brain disease).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The study drugs were provided by Grupo Uriach, Barcelona, Spain. Each patient was randomly assigned to one of the 2 groups: identical uncoated capsules of triflusal (600 mg/d) or aspirin (325 mg/d).<BR/>Treatment with any anticoagulant or antiplatelet agent other than the study drug was allowed only for 10 days during the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome event was a composite outcome and included the first occurrence of vascular death (including sudden death (unexpected cardiac death occurring within the first hour following appearance of the symptoms, or with the first 24 h after a convincing circumstantial phenomenon) or death attributable to stroke, MI, congestive heart failure or systemic bleeding), non-fatal ischemic stroke (any neurological deficit appeared after the qualifying event, which lasts more than 24 h, and without evidence of brain hemorrhage in the head CT), non-fatal AMI (requiring at least 2 of the following criteria: chest pain, ECG criterion, and enzymatic criterion); or major hemorrhage (requiring hospital admission and/or blood transfusion).<BR/>Secondary outcomes were the occurrence of each of these events separately as well as overall mortality, non-cardiovascular death, overall hemorrhage, minor systemic hemorrhage, any non-fatal systemic thromboembolism. Adverse event data were collected by closed and open questionnaire.<BR/>All outcome data were recorded at days 30, 60 and 90 after inclusion and at 3-month intervals thereafter until month 24.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Concerning baseline characteristics only the presence of old non-lacunar stroke was significantly different between groups.<BR/>Patients' treatment and follow up extended from a minimum of one year to a maximum of two years from inclusion. All subjects were followed until planned end of follow up regardless of whether or not they were on treatment, and event times were censored either at the planned end of follow up, at the time of loss-to-follow-up, or at the time of death, as appropriate.<BR/>Number and reasons for withdrawal were similar in both groups (47 patients in the aspirin group and 42 in triflusal group).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TIM">
<CHAR_METHODS>
<P>Randomised, multicentre, double-blind, sequential, aspirin-controlled, 2 arm, parallel, phase III study.<BR/>Method of randomisation: random list by an independent centre.<BR/>Data analysed on a per-protocol basis.<BR/>Location: 29 centres in Portugal, Spain, and Italy.<BR/>Duration: 35 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>2275 patients were enrolled and randomised to one of the treatment groups.<BR/>Triflusal arm: 1135 patients (for per-protocol analysis 1056 patients were considered because 4 patients did not receive the study medication and 75 patients had major protocol violations due to lack of inclusion criteria in 54 patients, loss of follow up at day 35 in 11 patients, and other reasons in 10 patients); 82.6% were male; mean age: 60.7±11.6 years; ethnicity: not mentioned; mean weight: 74.6±11.2 kg; active smoking habits: 53.8%; hypertension: 37.2%; hypercholesterolaemia: 37%; diabetes mellitus: 22.5%; history of previous AMI (5.6%), heart failure (6.9%), angina pectoris (39.3%), cerebrovascular event either ischemic or hemorrhagic (2.7%), and revascularization (0.6%); the qualifying event was AMI within 24 h of symptom onset (AMI localization: anterior in 35.7%, inferior in 49%, other in 7.2%, and non-Q wave in 8%).<BR/>Aspirin arm: 1140 patients (for per-protocol analysis 1068 patients were considered because 1 patient did not receive the study medication and 71 patients had major protocol violations due to lack of inclusion criteria in 53 patients, loss of follow up at day 35 in 9 patients, and other reasons in 9 patients); 80.9% were male; mean age: 60.9±11.6 years; ethnicity: not mentioned; mean weight: 74.8±10.8 kg; active smoking habits: 56.4%; hypertension: 39.3%; hypercholesterolaemia: 38.5%; diabetes mellitus: 21.4%; history of previous AMI (6.1%), heart failure (6.5%), angina pectoris (40.4%), cerebrovascular event either ischemic or hemorrhagic (2.5%), and revascularization (0.4%); the qualifying event was AMI within 24 h of symptom onset (AMI localization: anterior in 35%, inferior in 48.5%, other in 6.5%, and non-Q wave in 9.9%).<BR/>Inclusion criteria: Age 18-80 years; AMI within less than 24 h of symptom onset (AIM was defined based on clinical grounds and at least one of the two criteria: ECG and/or enzymatic criteria); informed consent.<BR/>Exclusion criteria: intake of drugs with antiplatelet activity in the previous 15 days; unfeasibility of oral route for drug administration; onset of symptoms more than 24 h before inclusion; history and/or presence of active peptic ulcer or blood dyscrasia; hepatic and/or renal disorders; history of cerebrovascular hemorrhage; hypersensitivity or severe adverse drug effects in general, and to salicylates in particular; severe, uncontrolled arterial hypertension (diastolic blood pressure &gt; 115 mmHg); pregnancy, breast-feeding or women not using reliable contraception; life expectancy of less than 1 year due to a cause unrelated to the study; pathological processes which require long-term treatment with NSAIDs; history of drug addiction; patients affected with AIDS or Known HIV infection; and participation in another trial during the last 3 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The study was sponsored by Grupo Uriach (Spain), Poli Industria Chimica (Italy), and Tecnifar Industria Técnica Farmacêutica (Portugal). Each patient was randomly assigned to one of the 2 groups: matched capsules of triflusal (600 mg/d) or aspirin (300 mg/d).<BR/>Treatment with drugs routinely administered following AMI was allowed. In the triflusal arm these concomitant medications included heparin (88.9%), nitrates (80.2%), fibrinolytic agents (70.7%), beta adrenergic blocking agents (40.9%), ACE inhibitors (27.1%), antiarrhythmic drugs (21.1%), diuretics (16.6%), calcium channel blocking agents (11.8%), non-glycoside inotropic agents (7.4%), and digitalis glycosides (4.4%). In the aspirin arm these concomitant medications included heparin (88%), nitrates (79.2%), fibrinolytic agents (70.7%), beta adrenergic blocking agents (41.9%), ACE inhibitors (30.6%), antiarrhythmic drugs (22.4%), diuretics (18.4%), calcium channel blocking agents (11.3%), non-glycoside inotropic agents (9%), and digitalis glycosides (5.8%).<BR/>Use of NSAIDs and antiplatelet or platelet-active drugs apart from the study medication was not allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome event was a composite outcome that included the first occurrence of death, non-fatal myocardial MI (based on clinical grounds and at least one of the two criteria: ECG and/or enzymatic criteria), or non-fatal cerebrovascular events (defined as an abnormal neurological finding due to an ischemic or hemorrhagic event, confirmed by CT) within the first 35 days after an AMI.<BR/>Secondary outcomes were the occurrence of each of these events separately, and urgent revascularization procedures within the first 35 days after an AMI. Adverse event data were collected on the basis of spontaneously and solicited report and by a structured questionnaire.<BR/>All outcome data were recorded at inclusion, day 15 or discharge (whichever occurred sooner), and day 35.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>441 patients failed to complete the 35-day treatment period for reasons other than death related to revascularization procedures (44.4%), administration of prohibited medications (14.2%), adverse events (13.1%), non-compliance (11.7%), and other causes (16.3%). There were no significant differences between the 2 treatment groups (data for each group not available).<BR/>60 patients were withdrawn due to adverse effects (34 in the aspirin group and 26 in the triflusal group).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACE: angiotensin-converting enzyme<BR/>AMI: acute myocardial infarction<BR/>BMI: body mass index<BR/>CT: computed tomography<BR/>d: day<BR/>ECG: electrocardiogram<BR/>h: hours<BR/>MI: myocardial infarction<BR/>MRI: magnetic resonance imaging<BR/>NSAID: non-steroidal anti-inflammatory drug<BR/>RIA: reversible ischemic attack<BR/>RIND: reversible ischemic neurological deficit<BR/>TIA: transient ischemic attack<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alvarez_x002d_Sabin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a randomised, parallel trial comparing two administration schedules of triflusal (600 mg once daily vs 300 mg bid) in 140 consecutive patients with ischemic transitory accident or ischemic stroke. We excluded this trial because it did not include a placebo or aspirin comparison.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arcas-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a prospective study without control group that aimed to evaluate the efficacy and tolerability of triflusal in 15 patients with peripheral arteriopathy who had undergone surgery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bescos-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a subgroup analysis of the TIM study considering only patients who had undergone fibrinolytic treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cesarone-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a pilot, randomised, parallel, double-dummy, double-blind clinical trial comparing triflusal (600 mg/day) vs acetylsalicylic acid (300 mg/day) on arteriosclerosis progression. The trial consisted of a 2-week run-in placebo phase, followed by a 12-month oral treatment. Forty-three patients were enrolled with subclinical atherosclerotic lesions. The primary outcome was identified in the ultrasonic biopsy score. This trial was excluded because it did not study patients at high vascular risk (see Type of participants in methods of the review) and evaluated only surrogate endpoints without considering clinical outcomes (see Type of outcomes in methods of the review).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-la-Torre-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a prospective study without control group that aimed to evaluate the efficacy and tolerability of triflusal in 50 patients with peripheral arteriopathy from whom 52% had surgery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garay-Lillo-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a prospective study without control group that aimed to evaluate the efficacy and tolerability of triflusal in 1381 patients with atherothrombotic stroke.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guiteras-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a randomised, double-blind, parallel, placebo-controlled trial comparing triflusal (300 mg tid) plus dipyridamole (75 mg tid) vs aspirin (50 mg tid) plus dipyridamole (75 mg tid) in 209 consecutive patients with aorto-coronary vein grafting. Patients received treatment for 6 months. Primary outcome was the prevention of aorto-coronary vein-graft occlusion assessed by angiography nine days after surgery. This was performed in 161 of the 209 randomised patients. Of these, 138 patients were recatheterized 6.5 +/- 1 months after surgery. We excluded this trial mainly because primary outcome was assessed at the 9th day.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kwon-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a prospective study without control group that aimed to evaluate the effect of triflusal in platelet aggregation tests from 35 patients at high thromboembolic risk.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lanas-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a case-control study that aimed to evaluate the risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drug therapy (namelly triflusal), common analgesics and individual non-steroidal anti-inflammatory drugs. We excluded this study because it was not a clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Masotti-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a retrospective study, during which 179 patients had undergone percutaneous transluminal coronary angioplasty (PTCA). The success rate was compared between patients not receiving antiplatelet therapy and patients treated orally with 300 mg triflusal three times daily or 300 mg acetylsalicylic acid plus 75 mg dipyridamole three times daily.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monreal-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a randomised, double-blind, parallel, placebo-controlled trial that studied the effect of a combination of low-dose heparin (7500 IU sc bid) and two different antiplatelets (aspirin 200 mg tid vs triflusal 300 mg tid vs placebo) on 459 consecutive patients with hip surgery. Primary outcome was to determine whether the benefits of antiplatelets plus heparin on pulmonary embolism outweigh the risks. We excluded this trial because patients were exposed to treatment drugs only for 9 days and our protocol required at least one month of therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-NASPEAF-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>This multi-centre, randomised trial in 1209 patients evaluated the efficacy and safety of the combination of antiplatelets (triflusal) and moderate intensity anticoagulation therapy in patients with atrial fibrillation in association with recognized risk factors or associated with mitral stenosis. The intermediate risk group included patients with risk factors or &gt; 60 years: 242 received triflusal, 237 acenocumarol and 235 the combination of both. High risk group included patients with prior embolism or mitral stenosis: 259 received anticoagulants and 236 the combined therapy. Median follow up was 2.76 years. Primary outcome was a composite of vascular death, and non-fatal stroke or systemic embolism. We excluded this trial because no placebo or aspirin arm as been used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perez-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a biochemical study comparing triflusal and different acenocoumarol doses in 15 healthy subjects and 99 patients with chronic atrial fibrillation. It was not randomised and outcomes were all biochemical.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pontes-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a subgroup analysis of the TACIP study considering patients who required antihipertensive therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Putz-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a randomised, double-blind, 2 arms, parallel trial comparing triflusal (300 mg tid) with aspirin (250 mg tid) in 99 patients who underwent hip surgery. Primary outcome was incidence of deep venous thrombosis. We excluded this trial because patients were exposed to treatment drugs only for 15 days and our protocol required at least one month of therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sala_x002d_Planell-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a prospective study without control group that aimed to evaluate the efficacy and tolerability of triflusal in 9 patients with advanced peripheral arteriopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zan-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a prospective study without control group that aimed to evaluate the compliance of 70 patients with peripheral arteriopathy treated with triflusal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>bid: twice a day<BR/>IU: international units<BR/>sc: subcutaneous<BR/>tid: three times a day<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Auteri-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-GEAIT">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Matias_x002d_Guiu-1994">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Smirne-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-TACIP">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-TAPIRSS">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-TIM">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Main results from excluded randomised trials</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Cesarone 1999</P>
</TH>
<TH>
<P>Monreal 1995</P>
</TH>
<TH>
<P>Putz 1991</P>
</TH>
<TH>
<P>Guiteras 1989</P>
</TH>
<TH>
<P>NASPEAF</P>
</TH>
</TR>
<TR>
<TD>
<P>Ultrasonic Biopsy Mean Score: aspirin (baseline): 19.5 +/- 4.4; triflusal (baseline): 20.5 +/- 4.2. Aspirin (week 48): 18.3 +/- 4.8; triflusal (week 48): 20.6 +/- 4.4 (P value not significant). Gastrointestinal adverse events (not hemorrhagic): aspirin (3/16), triflusal (2/15).</P>
</TD>
<TD>
<P>Deep venous thrombosis: aspirin (27/151), triflusal (21/154), placebo (27/154); P value not significant. Pulmonary embolism: aspirin (8/151), triflusal (3/154), placebo (8/154); P value not significant. Deaths: aspirin (11/151), triflusal (9/154), placebo (9/154); P value not significant. Mean postoperative haemoglobin level: aspirin (9.7+/-1.3), triflusal (9.8+/-1.5), placebo (9.7+/-1.5); P value not significant. Mean blood units transfusions 24 hrs after surgery: aspirin (1.1+/-1.7), triflusal (0.9+/-1.2), placebo (0.7+/-1.1); P value &lt; 0.05. Gastrointestinal adverse events (not hemorrhagic): aspirin (25/151), triflusal (60/154), placebo (29/154); P value &lt; 0.05.</P>
</TD>
<TD>
<P>Deep venous thrombosis: aspirin (11/51), triflusal (7/48); P value not significant. Adverse events not reported.</P>
</TD>
<TD>
<P>Patients with graft occlusion (day 9): aspirin (10/57), triflusal (9/53), placebo (13/51); P value not significant. Grafts occluded (day 9): aspirin (10/116), triflusal (9/94), placebo (12/94); P value not significant. Distal anastomoses occlusion (day 9): aspirin (10/127), triflusal (10/101), placebo (14/102); P value not significant. Patients with graft occlusion (6 month): aspirin (15/49), triflusal (9/44), placebo (18/45); P value &lt; 0.05. Patients with new graft occlusion (6 month): aspirin (9/45), triflusal (2/42), placebo (8/41); P value &lt; 0.05. Grafts occluded (6 month): aspirin (15/99), triflusal (9/81), placebo (21/86); P value &lt; 0.05. New grafts occluded (6 month): aspirin (8/92), triflusal (1/73), placebo (9/74); P value &lt; 0.05. Distal anastomoses occlusion (6 month): aspirin (17/108), triflusal (10/86), placebo (22/91); P value &lt; 0.05. New distal anastomoses occlusion (6 month): aspirin (10/99), triflusal (2/78), placebo (9/78); P value &lt; 0.05. Data on adverse events is available only for patients that failed angiography.</P>
</TD>
<TD>
<P>Primary outcome: primary events in the intermediate risk group were recorded in 42 cases. The combined arm presented fewer primary events than both the triflusal (HR: 0.24 (0.09 to 0.64); P value 0.001) or the anticoagulant alone (HR: 0.33, (0,12 to 0.91); P value 0.02). No significant difference in primary event was observed in the anticoagulant compared with the antiplatelet arm (HR, 0.72 (0.37 to 1.39), P value 0.32). The 'on treatment' primary outcome rates were 2.95, 2.34 and 0.55 in the triflusal, anticoagulant and combined arms, respectively, with a significant benefit in the combined arms when compared with either the triflusal (P value 0.002) or the anticoagulant arms (P value 0.005).<BR/>There were 43 primary events in the high risk group. The anticoagulant therapy presented a primary outcome rate of 4.76 and the combined therapy decreased this rate by 49% (HR: 0.51 (0.27 to 0.96); P value 0.03).<BR/>Adverse events: there were 42 severe bleeding episodes. The triflusal arm in the intermediate risk group showed significantly fewer events than the anticoagulant and the combined arms. No difference was found between the anticoagulant and the combined arms. Fourteen bleeding events were intracranial (2 in the triflusal arm, 9 in the anticoagulant and 3 in the combined arms). Fifteen hemorrhages were gastric, most of them in the combined arms.<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Aspirin versus triflusal: objective outcomes of safety and tolerability</TITLE>
<TABLE COLS="3" ROWS="9">
<TR>
<TH>
<P>Nº of patients (pts)</P>
</TH>
<TH>
<P>NNH (95% CI)</P>
</TH>
<TH>
<P>Benefit for 1000 pts</P>
</TH>
</TR>
<TR>
<TD>
<P>Serious adverse events related to medication</P>
</TD>
<TD>
<P>75 (45, 522)</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>Any hemorrhagic adverse event</P>
</TD>
<TD>
<P>20 (16, 28)</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
<TR>
<TD>
<P>Any major hemorrhage (intracranial/systemic)</P>
</TD>
<TD>
<P>60 (48, 97)</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Any major systemic hemorrhage (extracranial)</P>
</TD>
<TD>
<P>98 (76, 194)</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>Any intracerebral hemorrhage</P>
</TD>
<TD>
<P>188 (133, 884)</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>Any minor hemorrhage</P>
</TD>
<TD>
<P>26 (20, 42)</P>
</TD>
<TD>
<P>38</P>
</TD>
</TR>
<TR>
<TD>
<P>Gastrointestinal hemorrhage</P>
</TD>
<TD>
<P>53 (40, 93)</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
<TR>
<TD>
<P>Non-hemorrhagic gastrointestinal adverse events</P>
</TD>
<TD>
<P>24 (15, 81)</P>
</TD>
<TD>
<P>42</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>TIM results for primary composite outcome (*OR values &gt; 1 favours triflusal)</TITLE>
<TABLE COLS="4" ROWS="3">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>OR*</P>
</TH>
<TH>
<P>Lower Limit</P>
</TH>
<TH>
<P>Upper Limit</P>
</TH>
</TR>
<TR>
<TD>
<P>Sequentially adjusted</P>
</TD>
<TD>
<P>1.134</P>
</TD>
<TD>
<P>0.815</P>
</TD>
<TD>
<P>1.577</P>
</TD>
</TR>
<TR>
<TD>
<P>Unadjusted</P>
</TD>
<TD>
<P>1.054</P>
</TD>
<TD>
<P>0.790</P>
</TD>
<TD>
<P>1.407</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Aspirin versus triflusal for secondary prevention of serious vascular events</NAME>
<DICH_OUTCOME CHI2="3.0837718003335284" CI_END="1.2313351967957453" CI_START="0.8730641929521668" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0368387868150357" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="292" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.09037629363212138" LOG_CI_START="-0.05895382316731136" LOG_EFFECT_SIZE="0.015711235232405064" METHOD="PETO" NO="1" P_CHI2="0.5439056709154846" P_Q="0.8131185157574198" P_Z="0.6800307062520405" Q="0.05588726482323514" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2531" TOTAL_2="2511" WEIGHT="100.0" Z="0.4124212297980016">
<NAME>Primary outcome: serious vascular event (all studies)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.0278845355102932" CI_END="1.2639355546459203" CI_START="0.8250392270510389" DF="3.0" EFFECT_SIZE="1.0211740366105067" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="195" I2="0.9209246648367925" ID="CMP-001.01.01" LOG_CI_END="0.10172493076980008" LOG_CI_START="-0.08352540213273571" LOG_EFFECT_SIZE="0.009099764318532202" NO="1" P_CHI2="0.38734609392751795" P_Z="0.8473094231534751" STUDIES="4" TAU2="0.0" TOTAL_1="1463" TOTAL_2="1455" WEIGHT="64.97956734895942" Z="0.1925525320541173">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="3.0658335885434096" CI_START="0.9107654790154625" EFFECT_SIZE="1.671004307849454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="22" LOG_CI_END="0.48654857793560546" LOG_CI_START="-0.040593438923406645" LOG_EFFECT_SIZE="0.2229775695060994" ORDER="23637" O_E="5.35483870967742" SE="0.30964583009805097" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="10.429645045670021" WEIGHT="8.024898384366539"/>
<DICH_DATA CI_END="2.6843753536027317" CI_START="0.23403124061674943" EFFECT_SIZE="0.7926081593603946" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4288432427193289" LOG_CI_START="-0.6307261651460104" LOG_EFFECT_SIZE="-0.10094146121334077" ORDER="23638" O_E="-0.5999999999999996" SE="0.6223963151332588" STUDY_ID="STD-Smirne-1994" TOTAL_1="84" TOTAL_2="81" VAR="2.5814634146341464" WEIGHT="1.9862595030498524"/>
<DICH_DATA CI_END="1.2498055197122298" CI_START="0.7534330328988631" EFFECT_SIZE="0.970383822644692" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="140" LOG_CI_END="0.09684243837849267" LOG_CI_START="-0.12295534286489124" LOG_EFFECT_SIZE="-0.013056452243199282" ORDER="23639" O_E="-1.8035121025154126" SE="0.12911030471892815" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="59.989906873526884" WEIGHT="46.15812950868628"/>
<DICH_DATA CI_END="1.6096242049965668" CI_START="0.5053898796420611" EFFECT_SIZE="0.901935575987644" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.20672449420175554" LOG_CI_START="-0.29637345901209583" LOG_EFFECT_SIZE="-0.04482448240517015" ORDER="23640" O_E="-1.1818181818181834" SE="0.29552222809284895" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="11.450374604155405" WEIGHT="8.810279952856755"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4260961926258875" CI_START="0.7976428919283411" DF="0.0" EFFECT_SIZE="1.066543712772294" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="97" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.154148820409018" LOG_CI_START="-0.0981915006004251" LOG_EFFECT_SIZE="0.02797865990429649" NO="2" P_CHI2="1.0" P_Z="0.6638320015101811" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="35.020432651040586" Z="0.4346286437993697">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="1.4260961926258875" CI_START="0.7976428919283411" EFFECT_SIZE="1.066543712772294" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="97" LOG_CI_END="0.154148820409018" LOG_CI_START="-0.0981915006004251" LOG_EFFECT_SIZE="0.02797865990429649" ORDER="23641" O_E="2.932203389830505" SE="0.1482259536656812" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="45.514679987437354" WEIGHT="35.020432651040586"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3650760144381325" CI_END="1.1981508014101223" CI_START="0.8338615720334775" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.999545852273429" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="264" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.07851148257634953" LOG_CI_START="-0.07890603988002114" LOG_EFFECT_SIZE="-1.972786518358258E-4" METHOD="PETO" NO="2" P_CHI2="0.8331530214478208" P_Q="0.5754623600281932" P_Z="0.9960803849196908" Q="0.31362823011319607" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2336" TOTAL_2="2324" WEIGHT="99.99999999999999" Z="0.0049125287513527086">
<NAME>Primary outcome: serious vascular event (sensitivity analysis after excluding Matias-Guiu and Smirne studies)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.051447784324936414" CI_END="1.2093696648629635" CI_START="0.7605793509149914" DF="1.0" EFFECT_SIZE="0.9590732999712553" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="167" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.08255907081213334" LOG_CI_START="-0.11885546949163113" LOG_EFFECT_SIZE="-0.018148199339748868" NO="1" P_CHI2="0.820562903582184" P_Z="0.7239384395330098" STUDIES="2" TAU2="0.0" TOTAL_1="1268" TOTAL_2="1268" WEIGHT="61.08358344334836" Z="0.3532000920739539">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="1.2498055197122298" CI_START="0.7534330328988631" EFFECT_SIZE="0.970383822644692" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="140" LOG_CI_END="0.09684243837849267" LOG_CI_START="-0.12295534286489124" LOG_EFFECT_SIZE="-0.013056452243199282" ORDER="23642" O_E="-1.8035121025154126" SE="0.12911030471892815" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="59.989906873526884" WEIGHT="51.2931697142392"/>
<DICH_DATA CI_END="1.6096242049965668" CI_START="0.5053898796420611" EFFECT_SIZE="0.901935575987644" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.20672449420175554" LOG_CI_START="-0.29637345901209583" LOG_EFFECT_SIZE="-0.04482448240517015" ORDER="23643" O_E="-1.1818181818181834" SE="0.29552222809284895" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="11.450374604155405" WEIGHT="9.790413729109162"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4260961926258875" CI_START="0.7976428919283411" DF="0.0" EFFECT_SIZE="1.066543712772294" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="97" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.154148820409018" LOG_CI_START="-0.0981915006004251" LOG_EFFECT_SIZE="0.02797865990429649" NO="2" P_CHI2="1.0" P_Z="0.6638320015101811" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="38.916416556651626" Z="0.4346286437993697">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="1.4260961926258875" CI_START="0.7976428919283411" EFFECT_SIZE="1.066543712772294" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="97" LOG_CI_END="0.154148820409018" LOG_CI_START="-0.0981915006004251" LOG_EFFECT_SIZE="0.02797865990429649" ORDER="23644" O_E="2.932203389830505" SE="0.1482259536656812" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="45.514679987437354" WEIGHT="38.916416556651626"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.212886375834886" CI_END="1.3207781479470844" CI_START="0.8324589105758187" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0485673741597996" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="150" I2="28.78991426856422" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.12082987498482035" LOG_CI_START="-0.07963719367819946" LOG_EFFECT_SIZE="0.020596340653310428" METHOD="PETO" NO="3" P_CHI2="0.23937502093043272" P_Q="0.48695103502010606" P_Z="0.6871392685307953" Q="0.48325639875541837" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="100.00000000000001" Z="0.40274032201931786">
<NAME>Overall mortality</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7296299770794676" CI_END="1.3343735659231366" CI_START="0.704598602879241" DF="2.0" EFFECT_SIZE="0.9696379480344366" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="81" I2="46.375377388881766" ID="CMP-001.03.01" LOG_CI_END="0.12527742996075963" LOG_CI_START="-0.152058222299309" LOG_EFFECT_SIZE="-0.01339039616927472" NO="1" P_CHI2="0.1549249646315145" P_Z="0.8498866621910333" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="52.24860192635167" Z="0.1892630393288983">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="3.4397937903411053" CI_START="0.4507198814923318" EFFECT_SIZE="1.2451439473171773" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5365324081525551" LOG_CI_START="-0.34609328454722876" LOG_EFFECT_SIZE="0.0952195618026631" ORDER="23645" O_E="0.8156682027649769" SE="0.5184587009594953" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="3.7202460588814095" WEIGHT="5.158613011055604"/>
<DICH_DATA CI_END="1.1941384099415109" CI_START="0.5796120617071847" EFFECT_SIZE="0.8319477301789688" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="68" LOG_CI_END="0.07705466782354836" LOG_CI_START="-0.23686258545350705" LOG_EFFECT_SIZE="-0.07990395881497939" ORDER="23646" O_E="-5.411010915994304" SE="0.1843965484904073" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="29.409959371049883" WEIGHT="40.78079693248345"/>
<DICH_DATA CI_END="5.33064532167317" CI_START="0.848558692216593" EFFECT_SIZE="2.126820496146651" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7267797873900008" LOG_CI_START="-0.0713181134827178" LOG_EFFECT_SIZE="0.3277308369536415" ORDER="23647" O_E="3.4335664335664333" SE="0.4688066576209595" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="4.550011128666119" WEIGHT="6.309191982812621"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5952718021997137" CI_START="0.8179620891447281" DF="0.0" EFFECT_SIZE="1.1423098774329816" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="69" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.20283468873421986" LOG_CI_START="-0.08726682451546201" LOG_EFFECT_SIZE="0.05778393210937895" NO="2" P_CHI2="1.0" P_Z="0.4349250274104838" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="47.751398073648346" Z="0.7807916928859004">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="1.5952718021997137" CI_START="0.8179620891447281" EFFECT_SIZE="1.1423098774329816" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="69" LOG_CI_END="0.20283468873421986" LOG_CI_START="-0.08726682451546201" LOG_EFFECT_SIZE="0.05778393210937895" ORDER="23648" O_E="4.581920903954796" SE="0.17040706490851365" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="34.4369601109535" WEIGHT="47.751398073648346"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.978705458915698" CI_END="1.4512970196481225" CI_START="0.8560994282391783" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1146544526112034" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="110" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.16175630340497563" LOG_CI_START="-0.06747579300044797" LOG_EFFECT_SIZE="0.0471402552022639" METHOD="PETO" NO="4" P_CHI2="0.39492022409367866" P_Q="0.5820772847266875" P_Z="0.4201791326463332" Q="0.30288856706394185" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="100.0" Z="0.8061105217574417">
<NAME>Vascular mortality</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.675816891851756" CI_END="1.545523723304202" CI_START="0.6702309769951384" DF="2.0" EFFECT_SIZE="1.017771032717742" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="45" I2="25.256470048818173" ID="CMP-001.04.01" LOG_CI_END="0.1890756757345123" LOG_CI_START="-0.17377550364613883" LOG_EFFECT_SIZE="0.007650086044186694" NO="1" P_CHI2="0.2623940877751072" P_Z="0.9341339272257039" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="39.9111070491893" Z="0.08264486366466542">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="7.796704707487116" CI_START="0.6191093954333136" EFFECT_SIZE="2.19704645782114" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8919110860563275" LOG_CI_START="-0.20823260520389103" LOG_EFFECT_SIZE="0.3418392404262182" ORDER="23649" O_E="1.8847926267281103" SE="0.6462298500453528" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="2.39456136252628" WEIGHT="4.341622178217764"/>
<DICH_DATA CI_END="1.3549709818118172" CI_START="0.5155933643066836" EFFECT_SIZE="0.8358313508419536" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="37" LOG_CI_END="0.13192999441784212" LOG_CI_START="-0.28769268065830783" LOG_EFFECT_SIZE="-0.07788134312023288" ORDER="23650" O_E="-2.9515899383008986" SE="0.2464884365054722" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="16.459130925185907" WEIGHT="29.842345649303752"/>
<DICH_DATA CI_END="4.774425653591454" CI_START="0.5260792465841181" EFFECT_SIZE="1.5848426580305306" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6789211349818739" LOG_CI_START="-0.27894883044343316" LOG_EFFECT_SIZE="0.19998615226922034" ORDER="23651" O_E="1.4545454545454541" SE="0.5626575592236246" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="3.1587240287325256" WEIGHT="5.72713922166778"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.664289449390519" CI_START="0.8423847104700747" DF="0.0" EFFECT_SIZE="1.1840489795457079" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="65" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.22122886002032172" LOG_CI_START="-0.07448952432344537" LOG_EFFECT_SIZE="0.07336966784843815" NO="2" P_CHI2="1.0" P_Z="0.3307721422428941" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="60.088892950810695" Z="0.9725598011751491">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="1.664289449390519" CI_START="0.8423847104700747" EFFECT_SIZE="1.1840489795457079" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="65" LOG_CI_END="0.22122886002032172" LOG_CI_START="-0.07448952432344537" LOG_EFFECT_SIZE="0.07336966784843815" ORDER="23652" O_E="5.5988700564971765" SE="0.17370644279313963" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="33.14119365311849" WEIGHT="60.088892950810695"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9625382732621697" CI_END="1.419739998351307" CI_START="0.5572320303433079" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8894518547065398" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" I2="24.290952083845934" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.15220881789000135" LOG_CI_START="-0.253963927780117" LOG_EFFECT_SIZE="-0.05087755494505783" METHOD="PETO" NO="5" P_CHI2="0.2655379072890003" P_Q="0.619382949874014" P_Z="0.623416815479708" Q="0.24673582682597583" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="99.99999999999999" Z="0.4910136210604308">
<NAME>Non-vascular mortality</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.715802446436194" CI_END="1.4707783747096317" CI_START="0.5654903866072074" DF="2.0" EFFECT_SIZE="0.9119819251103992" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" I2="46.17582530744633" ID="CMP-001.05.01" LOG_CI_END="0.16754723568328045" LOG_CI_START="-0.2475747737251396" LOG_EFFECT_SIZE="-0.04001376902092958" NO="1" P_CHI2="0.15599978620869048" P_Z="0.7055469659925173" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="95.73484482162343" Z="0.3778433539502702">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="2.434050665445384" CI_START="0.09540628699549358" EFFECT_SIZE="0.48189598083928276" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38632961394924137" LOG_CI_START="-1.0204230056157613" LOG_EFFECT_SIZE="-0.31704669583326" ORDER="23653" O_E="-1.0691244239631335" SE="0.8263334522702559" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="1.464499847805928" WEIGHT="8.336544876993834"/>
<DICH_DATA CI_END="1.4175719611678277" CI_START="0.49482184460732875" EFFECT_SIZE="0.8375234759030299" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" LOG_CI_END="0.15154511451016014" LOG_CI_START="-0.30555113607806084" LOG_EFFECT_SIZE="-0.07700301078395035" ORDER="23654" O_E="-2.4594209776934015" SE="0.2685006002584532" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="13.871054500533518" WEIGHT="78.95983636199657"/>
<DICH_DATA CI_END="19.006504350311136" CI_START="0.7597500338190061" EFFECT_SIZE="3.800025305564421" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.278902249376269" LOG_CI_START="-0.11932927191612429" LOG_EFFECT_SIZE="0.5797864887300723" ORDER="23655" O_E="1.9790209790209792" SE="0.8213281169648085" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="1.4824041392239553" WEIGHT="8.438463582633016"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.882450924142914" CI_START="0.05271256448574326" DF="0.0" EFFECT_SIZE="0.5073130287971718" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.6886378866795966" LOG_CI_START="-1.278085854684022" LOG_EFFECT_SIZE="-0.2947239840022127" NO="2" P_CHI2="1.0" P_Z="0.556920326818853" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="4.265155178376563" Z="0.5874219971778917">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="4.882450924142914" CI_START="0.05271256448574326" EFFECT_SIZE="0.5073130287971718" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6886378866795966" LOG_CI_START="-1.278085854684022" LOG_EFFECT_SIZE="-0.2947239840022127" ORDER="23656" O_E="-0.5084745762711864" SE="1.1552632611165203" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="0.7492695357328384" WEIGHT="4.265155178376563"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.252528037580571" CI_END="1.4717544999268641" CI_START="0.9304684193383351" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1702226639409405" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="151" I2="52.019407478565164" I2_Q="64.9894749755104" ID="CMP-001.06" LOG_CI_END="0.16783537235267504" LOG_CI_START="-0.031298362500808155" LOG_EFFECT_SIZE="0.06826850492593349" METHOD="PETO" NO="6" P_CHI2="0.09995020302039037" P_Q="0.09101766357137453" P_Z="0.17899405118071673" Q="2.8562839297625717" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="99.99999999999997" Z="1.3438587995316194">
<NAME>Stroke (fatal and non-fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3962441078179997" CI_END="1.3957799322905293" CI_START="0.8613062265848795" DF="2.0" EFFECT_SIZE="1.0964460527650481" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="142" I2="41.111417892604045" ID="CMP-001.06.01" LOG_CI_END="0.14481695000211686" LOG_CI_START="-0.06484241315573482" LOG_EFFECT_SIZE="0.039987268423191065" NO="1" P_CHI2="0.1830271685027166" P_Z="0.45468457240170723" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="90.21134415517166" Z="0.7476280073462115">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="3.9008268847522722" CI_START="0.9914990628197677" EFFECT_SIZE="1.9666382993458742" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.5911566771343819" LOG_CI_START="-0.003707691960338407" LOG_EFFECT_SIZE="0.29372449258702177" ORDER="23657" O_E="5.539170506912441" SE="0.34942627503235607" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="8.190093935597131" WEIGHT="11.206081208227822"/>
<DICH_DATA CI_END="1.366338321326395" CI_START="0.7825933311472879" EFFECT_SIZE="1.0340634692130928" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="109" LOG_CI_END="0.13555824904737" LOG_CI_START="-0.10646385725091956" LOG_EFFECT_SIZE="0.014547195898225179" ORDER="23658" O_E="1.6573327005220762" SE="0.142164983268363" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="49.4782947552364" WEIGHT="67.69858727284388"/>
<DICH_DATA CI_END="1.7255826698344112" CI_START="0.4412894457522061" EFFECT_SIZE="0.8726290276920883" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.23693577046196682" LOG_CI_START="-0.3552764593789809" LOG_EFFECT_SIZE="-0.05917034445850702" ORDER="23659" O_E="-1.1258741258741267" SE="0.34786839530638897" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="8.263614563333537" WEIGHT="11.306675674099962"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.437564645700332" CI_START="1.0248653751397279" DF="0.0" EFFECT_SIZE="2.1325820864206997" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.6471446928386849" LOG_CI_START="0.01066682083193389" LOG_EFFECT_SIZE="0.3289057568353094" NO="2" P_CHI2="1.0" P_Z="0.04279978191522816" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="9.788655844828313" Z="2.0256586004242347">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="4.437564645700332" CI_START="1.0248653751397279" EFFECT_SIZE="2.1325820864206997" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6471446928386849" LOG_CI_START="0.01066682083193389" LOG_EFFECT_SIZE="0.3289057568353094" ORDER="23660" O_E="5.418079096045197" SE="0.37387025263304446" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="7.1541522306221275" WEIGHT="9.788655844828313"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.112657913491657" CI_END="1.3981222306990726" CI_START="0.8610639950074241" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0972113349188637" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="138" I2="50.921513317823674" I2_Q="72.81288203843641" ID="CMP-001.07" LOG_CI_END="0.14554514122198153" LOG_CI_START="-0.0649645702121056" LOG_EFFECT_SIZE="0.040290285504937955" METHOD="PETO" NO="7" P_CHI2="0.1062560471283065" P_Q="0.05512813610150258" P_Z="0.45310385287031096" Q="3.678212605741339" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="99.99999999999999" Z="0.7502505036803508">
<NAME>Stroke (non-fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.434445307750318" CI_END="1.3208757388501282" CI_START="0.7986143685097908" DF="2.0" EFFECT_SIZE="1.0270688117461744" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="133" I2="17.845761675861628" ID="CMP-001.07.01" LOG_CI_END="0.12086196336014236" LOG_CI_START="-0.09766288033204049" LOG_EFFECT_SIZE="0.011599541514050937" NO="1" P_CHI2="0.2960513346574217" P_Z="0.8351710847852964" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="92.79885876272542" Z="0.20807413217273776">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="3.5894055400352927" CI_START="0.846997245589203" EFFECT_SIZE="1.7436216922579617" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.5550225287845325" LOG_CI_START="-0.07211800198021999" LOG_EFFECT_SIZE="0.24145226340215625" ORDER="23661" O_E="4.096774193548388" SE="0.36838545216691" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="7.3687709561799055" WEIGHT="11.267161863330376"/>
<DICH_DATA CI_END="1.2979661960314295" CI_START="0.7258064819313841" EFFECT_SIZE="0.9706040791215711" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="102" LOG_CI_END="0.11326338193415948" LOG_CI_START="-0.13917915758150537" LOG_EFFECT_SIZE="-0.012957887823672947" ORDER="23662" O_E="-1.356905552918846" SE="0.1482859973222256" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="45.477828031505304" WEIGHT="69.53751889844511"/>
<DICH_DATA CI_END="1.745708650458241" CI_START="0.43066056143870274" EFFECT_SIZE="0.8670685483367195" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.24197176396495612" LOG_CI_START="-0.365864897760929" LOG_EFFECT_SIZE="-0.06194656689798644" ORDER="23663" O_E="-1.11888111888112" SE="0.35704626393778643" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="7.8442425491637975" WEIGHT="11.994178000949928"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.342340418040269" CI_START="1.0418095692893439" DF="0.0" EFFECT_SIZE="2.5705079146357304" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.8022495485880645" LOG_CI_START="0.017788342221722778" LOG_EFFECT_SIZE="0.4100189454048937" NO="2" P_CHI2="1.0" P_Z="0.040476611587052035" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="7.201141237274576" Z="2.0488517710011434">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="6.342340418040269" CI_START="1.0418095692893439" EFFECT_SIZE="2.5705079146357304" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8022495485880645" LOG_CI_START="0.017788342221722778" LOG_EFFECT_SIZE="0.4100189454048937" ORDER="23664" O_E="4.44632768361582" SE="0.4607963957651872" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="4.709576470475384" WEIGHT="7.201141237274576"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.704366232834639" CI_END="3.4505221088529936" CI_START="0.9455349761204979" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.8062639175374027" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.5378848144465807" LOG_CI_START="-0.024322401609863754" LOG_EFFECT_SIZE="0.2567812064183584" METHOD="PETO" NO="8" P_CHI2="0.8721765104618746" P_Q="0.7103752356209344" P_Z="0.07339304974625334" Q="0.1379025507728343" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="99.99999999999997" Z="1.7903787148694283">
<NAME>Stroke (fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5664636820618046" CI_END="4.15563093542714" CI_START="0.9119099407494405" DF="2.0" EFFECT_SIZE="1.946679521673227" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.618636970592392" LOG_CI_START="-0.04004805001241717" LOG_EFFECT_SIZE="0.2892944602899874" NO="1" P_CHI2="0.7533451339588585" P_Z="0.08513613742166684" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="72.85129177478059" Z="1.7216323594992298">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="19.035191630369944" CI_START="0.552300893789092" EFFECT_SIZE="3.242399320086895" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2795572532855746" LOG_CI_START="-0.2578242539565572" LOG_EFFECT_SIZE="0.5108664996645086" ORDER="23665" O_E="1.4423963133640552" SE="0.9030655075152242" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="1.2262005044820565" WEIGHT="13.373020970986998"/>
<DICH_DATA CI_END="4.431958159198782" CI_START="0.7617269517266642" EFFECT_SIZE="1.8373736633539206" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6465956516944569" LOG_CI_START="-0.11820067775427147" LOG_EFFECT_SIZE="0.2641974869700927" ORDER="23666" O_E="3.0142382534409116" SE="0.44924514972107044" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="4.954880743280008" WEIGHT="54.03824565918928"/>
<DICH_DATA CI_END="15.817229630357211" CI_START="0.061474136568821086" EFFECT_SIZE="0.9860783612051238" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.19913041964154" LOG_CI_START="-1.2113075624026637" LOG_EFFECT_SIZE="-0.006088571380561846" ORDER="23667" O_E="-0.006993006993007089" SE="1.4159032025132108" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="0.4988073817562087" WEIGHT="5.440025144604325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.117231724427933" CI_START="0.42661303888093133" DF="0.0" EFFECT_SIZE="1.47752420508637" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.7090350836443405" LOG_CI_START="-0.3699658750293444" LOG_EFFECT_SIZE="0.1695346043074981" NO="2" P_CHI2="1.0" P_Z="0.5379563979479725" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="27.148708225219387" Z="0.6159062527328766">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="5.117231724427933" CI_START="0.4266130388809314" EFFECT_SIZE="1.47752420508637" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7090350836443405" LOG_CI_START="-0.36996587502934436" LOG_EFFECT_SIZE="0.1695346043074981" ORDER="23668" O_E="0.9717514124293789" SE="0.6338105042658088" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="2.4893223299374827" WEIGHT="27.148708225219387"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2196649119034597" CI_END="1.3700894663326926" CI_START="0.8411933320106839" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.073550242577001" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="138" I2="6.822601665512894" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.13674892735055058" LOG_CI_START="-0.07510417854687064" LOG_EFFECT_SIZE="0.030822374401839995" METHOD="PETO" NO="9" P_CHI2="0.35898125537959147" P_Q="0.34487683542014236" P_Z="0.5684689262248876" Q="0.8922188712298498" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="100.00000000000001" Z="0.5703078412724938">
<NAME>Ischemic stroke (fatal and non-fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.32744604067361" CI_END="1.341348629359198" CI_START="0.8123461219139527" DF="2.0" EFFECT_SIZE="1.0438579200229026" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="133" I2="14.06889934079161" ID="CMP-001.09.01" LOG_CI_END="0.12754166981957396" LOG_CI_START="-0.09025888848166395" LOG_EFFECT_SIZE="0.018641390668954986" NO="1" P_CHI2="0.31232128124956215" P_Z="0.7372451010272676" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="94.61319173573344" Z="0.3355037711368909">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="3.5894055400352927" CI_START="0.846997245589203" EFFECT_SIZE="1.7436216922579617" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.5550225287845325" LOG_CI_START="-0.07211800198021999" LOG_EFFECT_SIZE="0.24145226340215625" ORDER="23669" O_E="4.096774193548388" SE="0.36838545216691" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="7.3687709561799055" WEIGHT="11.411426369604202"/>
<DICH_DATA CI_END="1.3252539578695766" CI_START="0.7429700579810756" EFFECT_SIZE="0.9922822229174567" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="102" LOG_CI_END="0.12229910992042259" LOG_CI_START="-0.1290286881446991" LOG_EFFECT_SIZE="-0.0033647891121382297" ORDER="23670" O_E="-0.35548172757475527" SE="0.14763119267611738" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="45.882148199488334" WEIGHT="71.05401415939276"/>
<DICH_DATA CI_END="1.745708650458241" CI_START="0.43066056143870274" EFFECT_SIZE="0.8670685483367195" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.24197176396495612" LOG_CI_START="-0.365864897760929" LOG_EFFECT_SIZE="-0.06194656689798644" ORDER="23671" O_E="-1.11888111888112" SE="0.35704626393778643" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="7.8442425491637975" WEIGHT="12.147751206736464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.025284824564741" CI_START="0.6142914332057602" DF="0.0" EFFECT_SIZE="1.7569830440698715" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.7011606818599341" LOG_CI_START="-0.21162554122839144" LOG_EFFECT_SIZE="0.2447675703157713" NO="2" P_CHI2="1.0" P_Z="0.29319172749801814" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="5.386808264266581" Z="1.0511456248301976">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="5.025284824564741" CI_START="0.6142914332057602" EFFECT_SIZE="1.7569830440698715" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7011606818599341" LOG_CI_START="-0.21162554122839144" LOG_EFFECT_SIZE="0.2447675703157713" ORDER="23672" O_E="1.9604519774011298" SE="0.536175145806758" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="3.4784570305748934" WEIGHT="5.386808264266581"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3577898222486533" CI_END="1.2790684274424038" CI_START="0.7731508056752266" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9944409410270877" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="133" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.1068937789319117" LOG_CI_START="-0.11173578721394509" LOG_EFFECT_SIZE="-0.0024210041410166892" METHOD="PETO" NO="10" P_CHI2="0.7154583296326547" P_Q="0.39705359562137754" P_Z="0.9653767030171431" Q="0.7172313773613281" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="100.00000000000001" Z="0.04340749521178146">
<NAME>Ischemic stroke (non-fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6405584448873252" CI_END="1.2552242864448697" CI_START="0.7482072456768593" DF="2.0" EFFECT_SIZE="0.969106756795977" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="128" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.09872133351622377" LOG_CI_START="-0.12597809038769225" LOG_EFFECT_SIZE="-0.01362837843573426" NO="1" P_CHI2="0.725946360130207" P_Z="0.8120750916841427" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="94.67032499247259" Z="0.2377498832675551">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="2.904221042824517" CI_START="0.5956241135103972" EFFECT_SIZE="1.315227768894268" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4630296678220042" LOG_CI_START="-0.22502772839380697" LOG_EFFECT_SIZE="0.11900096971409857" ORDER="23673" O_E="1.67741935483871" SE="0.404168320476209" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="6.12174817898023" WEIGHT="10.09644422920228"/>
<DICH_DATA CI_END="1.2599439376687414" CI_START="0.6960933455426884" EFFECT_SIZE="0.9365033853478922" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="99" LOG_CI_END="0.1003512212264649" LOG_CI_START="-0.15733251795290817" LOG_EFFECT_SIZE="-0.028490648363221613" ORDER="23674" O_E="-2.8633127669672547" SE="0.15136470394904458" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="43.64663516265438" WEIGHT="71.985289957727"/>
<DICH_DATA CI_END="1.8753598982485895" CI_START="0.4538230538950727" EFFECT_SIZE="0.9225408154523721" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.27308462503685466" LOG_CI_START="-0.34311344603348415" LOG_EFFECT_SIZE="-0.03501441049831477" ORDER="23675" O_E="-0.6153846153846168" SE="0.3619577971763623" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="7.632804291323343" WEIGHT="12.588590805543301"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.679112123540378" CI_START="0.5286214818299211" DF="0.0" EFFECT_SIZE="1.5727298510533405" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.6701634521277324" LOG_CI_START="-0.27685519222468113" LOG_EFFECT_SIZE="0.1966541299515256" NO="2" P_CHI2="1.0" P_Z="0.41564686542687634" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="5.329675007527426" Z="0.8139966713741236">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="4.679112123540378" CI_START="0.5286214818299211" EFFECT_SIZE="1.5727298510533405" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6701634521277324" LOG_CI_START="-0.27685519222468113" LOG_EFFECT_SIZE="0.1966541299515256" ORDER="23676" O_E="1.463276836158192" SE="0.5562834395105014" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="3.2315266178086257" WEIGHT="5.329675007527426"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.838491104135887" CI_END="6.54506972337486" CI_START="1.1214125754314084" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.7091924063949273" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.8159142773673972" LOG_CI_START="0.04976542193355293" LOG_EFFECT_SIZE="0.43283984965047506" METHOD="PETO" NO="11" P_CHI2="0.4172028416010459" P_Q="0.6106788107747144" P_Z="0.026788628013635112" Q="0.2591876939996989" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="100.0" Z="2.214584046877603">
<NAME>Ischemic stroke (fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.579303410136188" CI_END="6.353563439064346" CI_START="1.0392104603072971" DF="2.0" EFFECT_SIZE="2.5695699223997917" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="22.45968457451078" ID="CMP-001.11.01" LOG_CI_END="0.8030173706235013" LOG_CI_START="0.01670350953425047" LOG_EFFECT_SIZE="0.40986044007887584" NO="1" P_CHI2="0.2753668019319119" P_Z="0.04102925600956128" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="94.93676990164957" Z="2.043234237609741">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="18.648255478565574" CI_START="0.9228711943867939" EFFECT_SIZE="4.148486206646213" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.2706382103286533" LOG_CI_START="-0.03485890945147606" LOG_EFFECT_SIZE="0.6178896504385887" ORDER="23677" O_E="2.4193548387096775" SE="0.7668554704738139" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="1.700485605272286" WEIGHT="34.44089892336532"/>
<DICH_DATA CI_END="8.174432475278024" CI_START="0.76457989423488" EFFECT_SIZE="2.500001343475287" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9124576107010318" LOG_CI_START="-0.11657712658595899" LOG_EFFECT_SIZE="0.3979402420575364" ORDER="23678" O_E="2.507831039392501" SE="0.6044600984864797" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="2.736936521731286" WEIGHT="55.43272687069922"/>
<DICH_DATA CI_END="6.725722213069946" CI_START="0.0026475824825704405" EFFECT_SIZE="0.13344251314314676" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8277389260440038" LOG_CI_START="-2.5771505010345677" LOG_EFFECT_SIZE="-0.8747057874952818" ORDER="23679" O_E="-0.5034965034965035" SE="2.000048903940442" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="0.24998777446329898" WEIGHT="5.063144107585023"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="368.2472458217707" CI_START="0.14497028532896794" DF="0.0" EFFECT_SIZE="7.306497676615569" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="2.56613950737107" LOG_CI_START="-0.8387210063176864" LOG_EFFECT_SIZE="0.8637092505266919" NO="2" P_CHI2="1.0" P_Z="0.3200446536189797" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="5.063230098350431" Z="0.994366152352251">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="368.2472458217707" CI_START="0.14497028532896794" EFFECT_SIZE="7.306497676615569" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.56613950737107" LOG_CI_START="-0.8387210063176864" LOG_EFFECT_SIZE="0.8637092505266919" ORDER="23680" O_E="0.4971751412429378" SE="2.0000319200721415" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="0.24999202017300265" WEIGHT="5.063230098350431"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8556885459855879" CI_END="4.041474036089522" CI_START="1.145522769187006" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.151650652271101" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.6065397930766037" LOG_CI_START="0.05900372594269951" LOG_EFFECT_SIZE="0.33277175950965165" METHOD="PETO" NO="12" P_CHI2="0.8361059063339823" P_Q="0.6362166163096803" P_Z="0.01720093649885502" Q="0.22372446704830695" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="99.99999999999999" Z="2.382384295248393">
<NAME>Hemorrhagic stroke (fatal and non-fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6319640789372809" CI_END="4.148504960680937" CI_START="0.9106479600663943" DF="2.0" EFFECT_SIZE="1.9436634430295314" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.6178916137464023" LOG_CI_START="-0.040649480929109576" LOG_EFFECT_SIZE="0.2886210664086464" NO="1" P_CHI2="0.7290725919388772" P_Z="0.08579656264176361" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="69.12890884010581" Z="1.718000288559746">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="19.035191630369944" CI_START="0.552300893789092" EFFECT_SIZE="3.242399320086895" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2795572532855746" LOG_CI_START="-0.2578242539565572" LOG_EFFECT_SIZE="0.5108664996645086" ORDER="23681" O_E="1.4423963133640552" SE="0.9030655075152242" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="1.2262005044820565" WEIGHT="12.684173060921562"/>
<DICH_DATA CI_END="3.969426597943209" CI_START="0.6207942163995722" EFFECT_SIZE="1.5697761223899969" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.59872777544454" LOG_CI_START="-0.20705233781535082" LOG_EFFECT_SIZE="0.19583771881459464" ORDER="23682" O_E="2.0128144280968208" SE="0.4733192272047491" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="4.463666164561928" WEIGHT="46.17345524694489"/>
<DICH_DATA CI_END="19.296815446061178" CI_START="0.3776094614775348" EFFECT_SIZE="2.6993814270714944" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2854856432918276" LOG_CI_START="-0.42295713244599015" LOG_EFFECT_SIZE="0.43126425542291874" ORDER="23683" O_E="0.9860139860139858" SE="1.0035477433965256" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="0.9929420948308604" WEIGHT="10.271280532239354"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.40165426757407" CI_START="0.8687802340912181" DF="0.0" EFFECT_SIZE="2.7017015307647294" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.9243648061267384" LOG_CI_START="-0.06109006842139348" LOG_EFFECT_SIZE="0.43163736885267245" NO="2" P_CHI2="1.0" P_Z="0.0859863336909442" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="30.871091159894178" Z="1.7169608049699665">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="8.40165426757407" CI_START="0.8687802340912181" EFFECT_SIZE="2.7017015307647294" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9243648061267384" LOG_CI_START="-0.06109006842139348" LOG_EFFECT_SIZE="0.43163736885267245" ORDER="23684" O_E="2.9661016949152543" SE="0.5788610713898744" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="2.984360696780301" WEIGHT="30.871091159894178"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9008371627632417" CI_END="6.678374985426554" CI_START="1.202395786557243" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.8337342753910746" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" I2="0.0" I2_Q="47.35941217011469" ID="CMP-001.13" LOG_CI_END="0.824670800691607" LOG_CI_START="0.0800474457241068" LOG_EFFECT_SIZE="0.45235912320785693" METHOD="PETO" NO="13" P_CHI2="0.5932413874226906" P_Q="0.16811494980995123" P_Z="0.017248914655576503" Q="1.8996748349992327" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="99.99999999999999" Z="2.381358531533606">
<NAME>Hemorrhagic stroke (non-fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.001162327764008847" CI_END="5.336307201751075" CI_START="0.7011921798435892" DF="2.0" EFFECT_SIZE="1.934367307186223" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.7272408231920359" LOG_CI_START="-0.1541629360889606" LOG_EFFECT_SIZE="0.28653894355153764" NO="1" P_CHI2="0.9994190049937149" P_Z="0.20254138328378213" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="71.37128406005957" Z="1.274344484274264">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="18.193102651440793" CI_START="0.19250946505366928" EFFECT_SIZE="1.8714551715430854" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2599067699538187" LOG_CI_START="-0.7155479128072986" LOG_EFFECT_SIZE="0.27217942857326" ORDER="23685" O_E="0.4654377880184333" SE="1.160391859312268" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="0.7426610602617739" WEIGHT="14.208203364759179"/>
<DICH_DATA CI_END="7.251450158377068" CI_START="0.5288427306889278" EFFECT_SIZE="1.958284122187275" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8604248662679574" LOG_CI_START="-0.27667346094931766" LOG_EFFECT_SIZE="0.29187570265931984" ORDER="23686" O_E="1.5064072140484104" SE="0.6679371861349261" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="2.241448447403285" WEIGHT="42.88222053961486"/>
<DICH_DATA CI_END="18.62137799191203" CI_START="0.1993374074640593" EFFECT_SIZE="1.926638838058663" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2700118158579976" LOG_CI_START="-0.7004111943713293" LOG_EFFECT_SIZE="0.28480031074333423" ORDER="23687" O_E="0.4895104895104896" SE="1.1574362299599137" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="0.7464588218787293" WEIGHT="14.280860155685524"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="36.440333990156184" CI_START="1.47881585987998" DF="0.0" EFFECT_SIZE="7.340881680286537" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="1.5615823488008815" LOG_CI_START="0.16991409961098514" LOG_EFFECT_SIZE="0.8657482242059333" NO="2" P_CHI2="1.0" P_Z="0.014745788788891137" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="28.628715939940424" Z="2.4385629838302076">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="36.4403339901562" CI_START="1.4788158598799797" EFFECT_SIZE="7.340881680286537" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.5615823488008818" LOG_CI_START="0.169914099610985" LOG_EFFECT_SIZE="0.8657482242059333" ORDER="23688" O_E="2.983050847457627" SE="0.817472818443081" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="1.496419497107168" WEIGHT="28.628715939940424"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1604629812076106" CI_END="3.9082411328525835" CI_START="0.6139666007912024" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.549041485374055" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.5919813512178197" LOG_CI_START="-0.21185525342985076" LOG_EFFECT_SIZE="0.1900630488939845" METHOD="PETO" NO="14" P_CHI2="0.5397779258189224" P_Q="0.5010813618187605" P_Z="0.3540060436435307" Q="0.4526454680386054" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="100.0" Z="0.9268468951780636">
<NAME>Hemorrhagic stroke (fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7078175131690052" CI_END="6.026159592522705" CI_START="0.6242050824834781" DF="2.0" EFFECT_SIZE="1.9394740125892995" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.7800406290356747" LOG_CI_START="-0.20467269948750347" LOG_EFFECT_SIZE="0.2876839647740857" NO="1" P_CHI2="0.4257478412748097" P_Z="0.2521235131072237" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="66.637074936004" Z="1.14520682020732">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="114.78166931488506" CI_START="0.4426675426309919" EFFECT_SIZE="7.128121736804395" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.059872536572042" LOG_CI_START="-0.35392232029136167" LOG_EFFECT_SIZE="0.85297510814034" ORDER="23689" O_E="0.9769585253456221" SE="1.4178750473988073" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="0.49742095936536257" WEIGHT="11.090084180705574"/>
<DICH_DATA CI_END="4.641610451517102" CI_START="0.33850911091747043" EFFECT_SIZE="1.253486109683028" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6666686893608412" LOG_CI_START="-0.4704296378564339" LOG_EFFECT_SIZE="0.09811952575220363" ORDER="23690" O_E="0.5064072140484104" SE="0.6679371861349261" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="2.241448447403285" WEIGHT="49.97347116239187"/>
<DICH_DATA CI_END="367.28383082832283" CI_START="0.14458138558603595" EFFECT_SIZE="7.287139710785441" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5650018095415774" LOG_CI_START="-0.839887617536994" LOG_EFFECT_SIZE="0.8625570960022915" ORDER="23691" O_E="0.49650349650349646" SE="2.000048903940442" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="0.24998777446329898" WEIGHT="5.573519592906558"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.908119188806572" CI_START="0.19918051521012728" DF="0.0" EFFECT_SIZE="0.9887374316466455" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.6909151005937781" LOG_CI_START="-0.7007531485961183" LOG_EFFECT_SIZE="-0.0049190240011700685" NO="2" P_CHI2="1.0" P_Z="0.988945286911355" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="33.36292506399601" Z="0.013855471499035234">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="4.908119188806573" CI_START="0.19918051521012722" EFFECT_SIZE="0.9887374316466455" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6909151005937783" LOG_CI_START="-0.7007531485961184" LOG_EFFECT_SIZE="-0.0049190240011700685" ORDER="23692" O_E="-0.016949152542372836" SE="0.817472818443081" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="1.496419497107168" WEIGHT="33.36292506399601"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5933383651559991" CI_END="1.6315107922690886" CI_START="0.6269809234401685" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0113981130788579" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.21258995094486233" LOG_CI_START="-0.20274567283866923" LOG_EFFECT_SIZE="0.004922139053096538" METHOD="PETO" NO="15" P_CHI2="0.4508282665224709" P_Q="1.0" P_Z="0.9629475729990836" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="99.99999999999999" Z="0.04645503404251846">
<NAME>Acute myocardial infarction (fatal and non-fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5933383651559991" CI_END="1.6315107922690886" CI_START="0.6269809234401685" DF="2.0" EFFECT_SIZE="1.0113981130788579" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.21258995094486233" LOG_CI_START="-0.20274567283866923" LOG_EFFECT_SIZE="0.004922139053096538" NO="1" P_CHI2="0.4508282665224709" P_Z="0.9629475729990836" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="99.99999999999999" Z="0.04645503404251846">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="3.045763887873279" CI_START="0.5934901945677702" EFFECT_SIZE="1.3444816854168748" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.48369623315358445" LOG_CI_START="-0.22658645190785356" LOG_EFFECT_SIZE="0.12855489062286543" ORDER="23693" O_E="1.7004608294930872" SE="0.41722356516108433" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="5.744633684205559" WEIGHT="34.19289791613925"/>
<DICH_DATA CI_END="1.4630082526981374" CI_START="0.38461499167142954" EFFECT_SIZE="0.7501299266971868" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.16524677594838197" LOG_CI_START="-0.41497379166986226" LOG_EFFECT_SIZE="-0.12486350786074012" ORDER="23694" O_E="-2.475083056478404" SE="0.3408244335570876" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="8.60871948976201" WEIGHT="51.24035454365411"/>
<DICH_DATA CI_END="5.19235694199198" CI_START="0.42378109303629075" EFFECT_SIZE="1.483382182821384" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.715364539841831" LOG_CI_START="-0.3728584232108226" LOG_EFFECT_SIZE="0.17125305831550428" ORDER="23695" O_E="0.965034965034965" SE="0.6392275552876728" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="2.4473102219654734" WEIGHT="14.566747540206636"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>AMI patients</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.990540563427747" CI_END="1.3120806251140293" CI_START="0.6105620154958148" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8950455803827146" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="57" I2="24.82221512809042" I2_Q="72.23167463278148" ID="CMP-001.16" LOG_CI_END="0.11796052251395278" LOG_CI_START="-0.21427021768179966" LOG_EFFECT_SIZE="-0.048154847583923396" METHOD="PETO" NO="16" P_CHI2="0.2624874680420769" P_Q="0.05773716960008335" P_Z="0.5699195544418947" Q="3.6012254494127136" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="99.99999999999999" Z="0.5681699826445634">
<NAME>Acute myocardial infarction (non-fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3893151140150332" CI_END="2.088214025692644" CI_START="0.7465464384452938" DF="2.0" EFFECT_SIZE="1.248578689387398" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="27" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.3197750084172949" LOG_CI_START="-0.12694317208730316" LOG_EFFECT_SIZE="0.09641591816499588" NO="1" P_CHI2="0.8231165442375916" P_Z="0.39752793519160934" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="55.311109748867864" Z="0.8460444879422498">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="3.6535538226992355" CI_START="0.6507156235233693" EFFECT_SIZE="1.541889929214768" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5627155095816336" LOG_CI_START="-0.1866087658364057" LOG_EFFECT_SIZE="0.188053371872614" ORDER="23696" O_E="2.235023041474655" SE="0.4401567885955411" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="5.1616100481122045" WEIGHT="19.658031323856772"/>
<DICH_DATA CI_END="2.2379981204233435" CI_START="0.5168410767552176" EFFECT_SIZE="1.0754949364528659" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.3498597174514407" LOG_CI_START="-0.2866429774061626" LOG_EFFECT_SIZE="0.031608370022639026" ORDER="23697" O_E="0.520645467489322" SE="0.3738848336985102" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="7.15359423458409" WEIGHT="27.2445183248679"/>
<DICH_DATA CI_END="4.624061421178726" CI_START="0.33059955664363405" EFFECT_SIZE="1.236411200100767" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6650235941628687" LOG_CI_START="-0.480697733182455" LOG_EFFECT_SIZE="0.09216293049020677" ORDER="23698" O_E="0.4685314685314683" SE="0.6730023790946809" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="2.2078359520356776" WEIGHT="8.408560100143196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0505134602812871" CI_START="0.3345186559426532" DF="0.0" EFFECT_SIZE="0.5928038046292905" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.021401621414448214" LOG_CI_START="-0.47557965682884074" LOG_EFFECT_SIZE="-0.2270890177071962" NO="2" P_CHI2="1.0" P_Z="0.0732677503580858" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="44.68889025113212" Z="1.7911592064954955">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="1.0505134602812871" CI_START="0.3345186559426532" EFFECT_SIZE="0.5928038046292905" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="0.021401621414448214" LOG_CI_START="-0.47557965682884074" LOG_EFFECT_SIZE="-0.2270890177071962" ORDER="23699" O_E="-6.135593220338983" SE="0.2919292629371112" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="11.733963648704366" WEIGHT="44.68889025113212"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.670371141409546" CI_END="1.0237460922466117" CI_START="0.08533746958009444" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.295573850340039" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="45.50959772335359" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.010192257021005095" LOG_CI_START="-1.068860238951451" LOG_EFFECT_SIZE="-0.5293339909652229" METHOD="PETO" NO="17" P_CHI2="0.1595839638008857" P_Q="1.0" P_Z="0.05448782884682351" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="100.0" Z="1.9229380627115849">
<NAME>Acute myocardial infarction (fatal)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.670371141409546" CI_END="1.0237460922466117" CI_START="0.08533746958009444" DF="2.0" EFFECT_SIZE="0.295573850340039" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="45.50959772335359" ID="CMP-001.17.01" LOG_CI_END="0.010192257021005095" LOG_CI_START="-1.068860238951451" LOG_EFFECT_SIZE="-0.5293339909652229" NO="1" P_CHI2="0.1595839638008857" P_Z="0.05448782884682351" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="100.0" Z="1.9229380627115849">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="4.732877080737917" CI_START="0.05008071753530575" EFFECT_SIZE="0.48685303758912507" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6751252253954284" LOG_CI_START="-1.3003294573656887" LOG_EFFECT_SIZE="-0.3126021159851302" ORDER="23700" O_E="-0.5345622119815667" SE="1.160391859312268" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="0.7426610602617739" WEIGHT="29.836714908618458"/>
<DICH_DATA CI_END="0.6705207245781339" CI_START="0.027211438237750477" EFFECT_SIZE="0.13507713827287574" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.17358779435104557" LOG_CI_START="-1.565248503342934" LOG_EFFECT_SIZE="-0.8694181488469899" ORDER="23701" O_E="-2.9957285239677267" SE="0.8174683892934465" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="1.4964357127404837" WEIGHT="60.11992297586634"/>
<DICH_DATA CI_END="367.28383082832283" CI_START="0.14458138558603595" EFFECT_SIZE="7.287139710785441" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5650018095415774" LOG_CI_START="-0.839887617536994" LOG_EFFECT_SIZE="0.8625570960022915" ORDER="23702" O_E="0.49650349650349646" SE="2.000048903940442" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="0.24998777446329898" WEIGHT="10.043362115515214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>AMI patients</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.722442862543301" CI_END="2.162477758071948" CI_START="0.46263313494961017" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.00021690871312" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.3349516492715127" LOG_CI_START="-0.33476326518747923" LOG_EFFECT_SIZE="9.419204201674209E-5" METHOD="PETO" NO="18" P_CHI2="0.8679129184445512" P_Q="1.0" P_Z="0.9995601117437811" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2442" TOTAL_2="2435" WEIGHT="100.00000000000001" Z="5.513181982283139E-4">
<NAME>Non-fatal systemic thromboembolism</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.86610368682773" CI_START="0.06504589728805531" EFFECT_SIZE="1.047411498916776" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2270147658878419" LOG_CI_START="-1.1867800909755617" LOG_EFFECT_SIZE="0.020117337456140125" ORDER="23703" O_E="0.02304147465437789" SE="1.4178750473988073" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="106" TOTAL_2="111" VAR="0.49742095936536257" WEIGHT="7.698023388561825"/>
<DICH_DATA CI_END="3.8238173751572746" CI_START="0.46741415811771747" EFFECT_SIZE="1.336901783679354" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5824971422715806" LOG_CI_START="-0.330298136831953" LOG_EFFECT_SIZE="0.12609950271981388" ORDER="23704" O_E="1.0099667774086383" SE="0.5361804653549193" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="3.4783880100524875" WEIGHT="53.831089646966824"/>
<DICH_DATA CI_END="3.8321493682770242" CI_START="0.1131263665573524" EFFECT_SIZE="0.6584201805368917" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5834424285260864" LOG_CI_START="-0.9464361615128601" LOG_EFFECT_SIZE="-0.18149686649338687" ORDER="23705" O_E="-0.5174825174825175" SE="0.898658256810034" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="1.2382572006126022" WEIGHT="19.163110664923593"/>
<DICH_DATA CI_END="3.829131102136556" CI_START="0.11454174993282397" EFFECT_SIZE="0.6622653374297374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5831002360159443" LOG_CI_START="-0.9410361861575272" LOG_EFFECT_SIZE="-0.17896797507079149" ORDER="23706" O_E="-0.5141242937853105" SE="0.8952852789816647" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="1.247605018244448" WEIGHT="19.307776299547776"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0492235961818484" CI_END="1.1598102492186877" CI_START="0.907127534009658" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.025717217995718" ESTIMABLE="YES" EVENTS_1="1452" EVENTS_2="1435" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.06438694228032248" LOG_CI_START="-0.0423316507315403" LOG_EFFECT_SIZE="0.011027645774391111" METHOD="PETO" NO="19" P_CHI2="0.7267057497054057" P_Q="0.8793328910405969" P_Z="0.6854324183449529" Q="0.023047784192883114" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2611" TOTAL_2="2596" WEIGHT="100.0" Z="0.4050613476448158">
<NAME>Number of patients with at least one adverse event</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0261758119889652" CI_END="1.234454144125647" CI_START="0.8689887771651733" DF="3.0" EFFECT_SIZE="1.035725251777819" ESTIMABLE="YES" EVENTS_1="1047" EVENTS_2="1037" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.09147496196898225" LOG_CI_START="-0.06098583235076958" LOG_EFFECT_SIZE="0.015244564809106362" NO="1" P_CHI2="0.5669916691349841" P_Z="0.6950923109964193" STUDIES="4" TAU2="0.0" TOTAL_1="1472" TOTAL_2="1465" WEIGHT="48.9963609570837" Z="0.3919538543551226">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="2.395962743264767" CI_START="0.8166521463580496" EFFECT_SIZE="1.3988095355984291" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="40" LOG_CI_END="0.37948006057857353" LOG_CI_START="-0.08796289216652134" LOG_EFFECT_SIZE="0.14575858420602616" ORDER="23707" O_E="4.451612903225808" SE="0.27457830432240266" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="13.26378772112383" WEIGHT="5.212222520166555"/>
<DICH_DATA CI_END="2.817955649768975" CI_START="0.552182281320258" EFFECT_SIZE="1.247407383074488" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.44993415370869105" LOG_CI_START="-0.25791753331482803" LOG_EFFECT_SIZE="0.0960083101969315" ORDER="23708" O_E="1.278688524590164" SE="0.4157955848799764" STUDY_ID="STD-Smirne-1994" TOTAL_1="93" TOTAL_2="90" VAR="5.78415940415403" WEIGHT="2.2729801275808077"/>
<DICH_DATA CI_END="1.1882021032997483" CI_START="0.7651689427439855" EFFECT_SIZE="0.9535068679081699" ESTIMABLE="YES" EVENTS_1="854" EVENTS_2="864" LOG_CI_END="0.07489031680911289" LOG_CI_START="-0.11624266576005397" LOG_EFFECT_SIZE="-0.02067617447547059" ORDER="23709" O_E="-3.7769340294257745" SE="0.11227246008465121" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="79.3329350861408" WEIGHT="31.17517556379128"/>
<DICH_DATA CI_END="1.6068801271185964" CI_START="0.7482383327252677" EFFECT_SIZE="1.09650777799548" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="121" LOG_CI_END="0.2059834797050297" LOG_CI_START="-0.12596004638558586" LOG_EFFECT_SIZE="0.040011716659721905" ORDER="23710" O_E="2.4232558139534888" SE="0.19498527037258204" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="214" VAR="26.30246128128227" WEIGHT="10.335982745545056"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2069575081211992" CI_START="0.8555815119232765" DF="0.0" EFFECT_SIZE="1.0161941397319145" ESTIMABLE="YES" EVENTS_1="405" EVENTS_2="398" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.08169198069111176" LOG_CI_START="-0.06773860857509212" LOG_EFFECT_SIZE="0.006976686058009823" NO="2" P_CHI2="1.0" P_Z="0.8547858946732495" STUDIES="1" TAU2="0.0" TOTAL_1="1139" TOTAL_2="1131" WEIGHT="51.0036390429163" Z="0.18301545182000561">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="1.2069575081211992" CI_START="0.8555815119232765" EFFECT_SIZE="1.0161941397319145" ESTIMABLE="YES" EVENTS_1="405" EVENTS_2="398" LOG_CI_END="0.08169198069111176" LOG_CI_START="-0.06773860857509212" LOG_EFFECT_SIZE="0.006976686058009823" ORDER="23711" O_E="2.085022026431716" SE="0.08777626782831464" STUDY_ID="STD-TIM" TOTAL_1="1139" TOTAL_2="1131" VAR="129.79135841814517" WEIGHT="51.0036390429163"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.886621473755917" CI_END="1.7770079618267207" CI_START="1.0376038441670237" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3578771271020118" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="103" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.24968937365204572" LOG_CI_START="0.016031572075091965" LOG_EFFECT_SIZE="0.13286047286356883" METHOD="PETO" NO="20" P_CHI2="0.4215675170444483" P_Q="0.6701691388433781" P_Z="0.02581953104498192" Q="0.18140434880370737" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2611" TOTAL_2="2596" WEIGHT="100.00000000000001" Z="2.228915448353172">
<NAME>Number of patients with serious adverse events related to medication</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7052171249522097" CI_END="1.8488508347946278" CI_START="1.0415172696773658" DF="3.0" EFFECT_SIZE="1.3876635303617442" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="91" I2="19.0330850033871" ID="CMP-001.20.01" LOG_CI_END="0.266901873712551" LOG_CI_START="0.01766647549682571" LOG_EFFECT_SIZE="0.14228417460468834" NO="1" P_CHI2="0.29510536489314254" P_Z="0.025232859302626337" STUDIES="4" TAU2="0.0" TOTAL_1="1472" TOTAL_2="1465" WEIGHT="87.89033592842188" Z="2.2378190240362312">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="3.111898447773673" CI_START="0.9709616008775046" EFFECT_SIZE="1.7382559934079178" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="25" LOG_CI_END="0.4930254159875939" LOG_CI_START="-0.012797945021720127" LOG_EFFECT_SIZE="0.24011373548293694" ORDER="23712" O_E="6.2626728110599075" SE="0.2971231461228899" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="11.327316358385186" WEIGHT="21.338446898612585"/>
<DICH_DATA CI_END="3.781949577394228" CI_START="0.1090986877407706" EFFECT_SIZE="0.6423439390197998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5777157343436512" LOG_CI_START="-0.9621804731547343" LOG_EFFECT_SIZE="-0.19223236940554148" ORDER="23713" O_E="-0.540983606557377" SE="0.9045426548937147" STUDY_ID="STD-Smirne-1994" TOTAL_1="93" TOTAL_2="90" VAR="1.2221989244295077" WEIGHT="2.302383549937188"/>
<DICH_DATA CI_END="1.731927360434569" CI_START="0.8560684303329972" EFFECT_SIZE="1.2176404793279472" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="60" LOG_CI_END="0.23852967311782433" LOG_CI_START="-0.06749151835066884" LOG_EFFECT_SIZE="0.0855190773835778" ORDER="23714" O_E="6.093972472710021" SE="0.1797583626979215" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="30.947230708507387" WEIGHT="58.29852528518404"/>
<DICH_DATA CI_END="9.034981295059774" CI_START="0.9956405005385579" EFFECT_SIZE="2.9992654599034454" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.9559272577867421" LOG_CI_START="-0.001897445528028423" LOG_EFFECT_SIZE="0.477014906129357" ORDER="23715" O_E="3.4697674418604647" SE="0.5626309720358446" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="214" VAR="3.159022567481194" WEIGHT="5.950980194688053"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.51298518559772" CI_START="0.5354748308217637" DF="0.0" EFFECT_SIZE="1.1600173779368728" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="0.40018992837286765" LOG_CI_START="-0.27126093770254883" LOG_EFFECT_SIZE="0.0644644953351594" NO="2" P_CHI2="1.0" P_Z="0.7066615345334956" STUDIES="1" TAU2="0.0" TOTAL_1="1139" TOTAL_2="1131" WEIGHT="12.109664071578136" Z="0.37634351379113873">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="2.51298518559772" CI_START="0.5354748308217637" EFFECT_SIZE="1.1600173779368728" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.40018992837286765" LOG_CI_START="-0.27126093770254883" LOG_EFFECT_SIZE="0.0644644953351594" ORDER="23716" O_E="0.9541850220264312" SE="0.3944135624680912" STUDY_ID="STD-TIM" TOTAL_1="1139" TOTAL_2="1131" VAR="6.428302705641388" WEIGHT="12.109664071578136"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4498153946689154" CI_END="2.0820044882159423" CI_START="1.439659606969657" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7312936675255373" ESTIMABLE="YES" EVENTS_1="336" EVENTS_2="212" I2="13.038825073481503" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.31848166139224854" LOG_CI_START="0.15825981967168473" LOG_EFFECT_SIZE="0.23837074053196664" METHOD="PETO" NO="21" P_CHI2="0.3273295692808109" P_Q="0.5622617023965484" P_Z="5.4803092927543506E-9" Q="0.3358035995697968" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2518" TOTAL_2="2506" WEIGHT="100.0" Z="5.831889852141601">
<NAME>Overall hemorrhagic adverse event</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1140117950991186" CI_END="2.162045256794272" CI_START="1.4503535165034585" DF="2.0" EFFECT_SIZE="1.770799237923711" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="185" I2="35.774167485568555" ID="CMP-001.21.01" LOG_CI_END="0.3348647805378784" LOG_CI_START="0.16147387227226548" LOG_EFFECT_SIZE="0.24816932640507194" NO="1" P_CHI2="0.21076628430925126" P_Z="2.0176847283807683E-8" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1375" WEIGHT="85.38681140547274" Z="5.610478042786401">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="9.79068967689011" CI_START="1.2064256309774373" EFFECT_SIZE="3.4368210560264023" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.990813285502618" LOG_CI_START="0.08150055537734058" LOG_EFFECT_SIZE="0.5361569204399793" ORDER="23717" O_E="4.3271889400921655" SE="0.5341347988461962" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="3.5050825741326705" WEIGHT="3.1046803779306527"/>
<DICH_DATA CI_END="2.0620479144018398" CI_START="1.3552136080554176" EFFECT_SIZE="1.671680410263776" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="176" LOG_CI_END="0.3142987524695923" LOG_CI_START="0.13200775387336852" LOG_EFFECT_SIZE="0.2231532531714804" ORDER="23718" O_E="44.81395348837211" SE="0.10707863493041786" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="87.21563515506188" WEIGHT="77.25257975746345"/>
<DICH_DATA CI_END="6.484123366927188" CI_START="1.2514846252024243" EFFECT_SIZE="2.84864541521495" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.8118512691416285" LOG_CI_START="0.09742551856209039" LOG_EFFECT_SIZE="0.45463839385185945" ORDER="23719" O_E="5.9441860465116285" SE="0.4196572223549215" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="214" VAR="5.678198837398405" WEIGHT="5.029551270078637"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4585640441559264" CI_START="0.9365933394587022" DF="0.0" EFFECT_SIZE="1.517456657828846" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="27" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="0.3906815258908719" LOG_CI_START="-0.0284489350085807" LOG_EFFECT_SIZE="0.18111629544114563" NO="2" P_CHI2="1.0" P_Z="0.09028530976136823" STUDIES="1" TAU2="0.0" TOTAL_1="1139" TOTAL_2="1131" WEIGHT="14.61318859452726" Z="1.6938946184735535">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="2.4585640441559264" CI_START="0.9365933394587023" EFFECT_SIZE="1.517456657828846" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="27" LOG_CI_END="0.3906815258908719" LOG_CI_START="-0.028448935008580648" LOG_EFFECT_SIZE="0.18111629544114563" ORDER="23720" O_E="6.880176211453744" SE="0.2461993074615807" STUDY_ID="STD-TIM" TOTAL_1="1139" TOTAL_2="1131" VAR="16.497811838953773" WEIGHT="14.61318859452726"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6501890704528117" CI_END="3.4609126149745646" CI_START="1.5822927435966667" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.340123269594236" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.5391906338756196" LOG_CI_START="0.19928683641006018" LOG_EFFECT_SIZE="0.3692387351428399" METHOD="PETO" NO="22" P_CHI2="0.6480641418476484" P_Q="0.7375660407741242" P_Z="2.0605000030880124E-5" Q="0.11227748832233964" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="100.0" Z="4.258232052558449">
<NAME>Number of patients with any intracranial hemorrhage or other major systemic hemorrhage</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.537911582130472" CI_END="3.7723461147079678" CI_START="1.557631666934703" DF="2.0" EFFECT_SIZE="2.4240308923170146" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="23" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="0.576611532636816" LOG_CI_START="0.1924647678874254" LOG_EFFECT_SIZE="0.3845381502621207" NO="1" P_CHI2="0.4634969331909814" P_Z="8.711903809197069E-5" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="78.29205154429482" Z="3.9239217630120824">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="12.151401881152113" CI_START="1.079288697975394" EFFECT_SIZE="3.621445942560017" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.0846263844468935" LOG_CI_START="0.03313762926796237" LOG_EFFECT_SIZE="0.5588820068574278" ORDER="23721" O_E="3.3732718894009217" SE="0.6176496997453866" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="2.621292776562585" WEIGHT="10.449674628038458"/>
<DICH_DATA CI_END="3.4520992839689453" CI_START="1.2568117904422678" EFFECT_SIZE="2.0829400091864096" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="20" LOG_CI_END="0.5380832777325679" LOG_CI_START="0.09927024626807032" LOG_EFFECT_SIZE="0.3186767620003191" ORDER="23722" O_E="11.044138585666825" SE="0.2577609468417838" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="15.051014121717113" WEIGHT="60.00024178916847"/>
<DICH_DATA CI_END="18.323936263479585" CI_START="1.1200615942938041" EFFECT_SIZE="4.530335226560061" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.2630187724913384" LOG_CI_START="0.049241905997310424" LOG_EFFECT_SIZE="0.6561303392443245" ORDER="23723" O_E="2.9720279720279716" SE="0.7129785396709818" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="1.9671935149354929" WEIGHT="7.842135127087897"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.773398177672213" CI_START="0.8897988376581478" DF="0.0" EFFECT_SIZE="2.060913426171089" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" ID="CMP-001.22.02" LOG_CI_END="0.6788276629757658" LOG_CI_START="-0.05070816590532902" LOG_EFFECT_SIZE="0.3140597485352184" NO="2" P_CHI2="1.0" P_Z="0.09150728125816922" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="21.707948455705186" Z="1.6874998368943999">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="4.773398177672213" CI_START="0.8897988376581479" EFFECT_SIZE="2.060913426171089" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6788276629757658" LOG_CI_START="-0.05070816590532897" LOG_EFFECT_SIZE="0.3140597485352184" ORDER="23724" O_E="3.9378531073446332" SE="0.42853295714534967" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="5.445422035271001" WEIGHT="21.707948455705186"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.115207870294144" CI_END="3.8620420928636876" CI_START="1.4142792710803551" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.337093510319368" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="18" I2="3.6982402167360338" I2_Q="41.083679856457664" ID="CMP-001.23" LOG_CI_END="0.5868170028972353" LOG_CI_START="0.15053517601921712" LOG_EFFECT_SIZE="0.3686760894582262" METHOD="PETO" NO="23" P_CHI2="0.3742015012884067" P_Q="0.19263858531799183" P_Z="9.246600248803774E-4" Q="1.6973225713412234" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2430" WEIGHT="99.99999999999997" Z="3.3125003737605745">
<NAME>Number of patients with any major systemic hemorrhage (extracranial)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4178852989529207" CI_END="4.559828324046955" CI_START="1.5522403353369234" DF="2.0" EFFECT_SIZE="2.660441588683624" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="14" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="0.6589484919357935" LOG_CI_START="0.19095896449295374" LOG_EFFECT_SIZE="0.4249537282143736" NO="1" P_CHI2="0.49216437863623463" P_Z="3.7162416945212337E-4" STUDIES="3" TAU2="0.0" TOTAL_1="1379" TOTAL_2="1374" WEIGHT="86.9084444658534" Z="3.559455729478582">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="18.87876476669767" CI_START="0.7399816589776671" EFFECT_SIZE="3.7376382478123897" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.275973575102053" LOG_CI_START="-0.13077904446294977" LOG_EFFECT_SIZE="0.5725972653195516" ORDER="23725" O_E="1.9308755760368665" SE="0.8263334522702559" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="1.464499847805928" WEIGHT="9.618310234839562"/>
<DICH_DATA CI_END="4.2005824181224005" CI_START="1.272604124766917" EFFECT_SIZE="2.3120723413695248" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="13" LOG_CI_END="0.6233095102646989" LOG_CI_START="0.10469332653859" LOG_EFFECT_SIZE="0.3640014184016444" ORDER="23726" O_E="9.031324157570005" SE="0.30463771351222896" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="10.775381763991687" WEIGHT="70.76884634722002"/>
<DICH_DATA CI_END="52.82835921029587" CI_START="1.0337710037131245" EFFECT_SIZE="7.390022051749579" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7228671221959226" LOG_CI_START="0.014424346458104843" LOG_EFFECT_SIZE="0.8686457343270138" ORDER="23727" O_E="1.9860139860139858" SE="1.0035477433965256" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="213" VAR="0.9929420948308604" WEIGHT="6.521287883793826"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9625164252061986" CI_START="0.24670705999294626" DF="0.0" EFFECT_SIZE="0.9887268467258188" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="0.5979710754432543" LOG_CI_START="-0.6078184221677142" LOG_EFFECT_SIZE="-0.004923673362229838" NO="2" P_CHI2="1.0" P_Z="0.9872292224310811" STUDIES="1" TAU2="0.0" TOTAL_1="1068" TOTAL_2="1056" WEIGHT="13.091555534146572" Z="0.01600647954013483">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="3.9625164252061986" CI_START="0.24670705999294626" EFFECT_SIZE="0.9887268467258188" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5979710754432543" LOG_CI_START="-0.6078184221677142" LOG_EFFECT_SIZE="-0.004923673362229838" ORDER="23728" O_E="-0.02259887005649741" SE="0.7082867196509589" STUDY_ID="STD-TIM" TOTAL_1="1068" TOTAL_2="1056" VAR="1.9933419300464386" WEIGHT="13.091555534146572"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.95959089162758" CI_END="1.949790092280025" CI_START="1.312739248144473" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.5998643629318152" ESTIMABLE="YES" EVENTS_1="280" EVENTS_2="188" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.2899878592233388" LOG_CI_START="0.11817846992946371" LOG_EFFECT_SIZE="0.20408316457640124" METHOD="PETO" NO="24" P_CHI2="0.6189100250070521" P_Q="0.7432421309721406" P_Z="3.2198597693530585E-6" Q="0.10729752376795443" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2500" TOTAL_2="2490" WEIGHT="100.0" Z="4.656272326729778">
<NAME>Number of patients with any minor hemorrhage</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8522933678596256" CI_END="2.0073840262222267" CI_START="1.3097726194497585" DF="1.0" EFFECT_SIZE="1.621485934032944" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="165" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.30263046392499554" LOG_CI_START="0.11719590734322384" LOG_EFFECT_SIZE="0.20991318563410966" NO="1" P_CHI2="0.35590444531903065" P_Z="9.105823335553069E-6" STUDIES="3" TAU2="0.0" TOTAL_1="1361" TOTAL_2="1359" WEIGHT="85.84449457361798" Z="4.437385256630951">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23729" O_E="0.0" SE="0.0" STUDY_ID="STD-Smirne-1994" TOTAL_1="93" TOTAL_2="90" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9721963512496679" CI_START="1.2722445074264743" EFFECT_SIZE="1.5840189315295206" ESTIMABLE="YES" EVENTS_1="233" EVENTS_2="160" LOG_CI_END="0.29495015098002264" LOG_CI_START="0.10457058459974548" LOG_EFFECT_SIZE="0.19976036778988407" ORDER="23730" O_E="36.7797816801139" SE="0.11182989968582709" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="79.96208860649018" WEIGHT="81.44287976119529"/>
<DICH_DATA CI_END="6.415488759186174" CI_START="0.9734437957582797" EFFECT_SIZE="2.499023355110305" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8072297483698232" LOG_CI_START="-0.011689118511374677" LOG_EFFECT_SIZE="0.39777031492922427" ORDER="23731" O_E="3.9581395348837205" SE="0.4810369961197842" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="214" VAR="4.32158482944854" WEIGHT="4.401614812422693"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.494899395014926" CI_START="0.8717706785012267" DF="0.0" EFFECT_SIZE="1.47478138664158" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" I2="0.0" ID="CMP-001.24.02" LOG_CI_END="0.39705303770658884" LOG_CI_START="-0.05959774231451411" LOG_EFFECT_SIZE="0.16872764769603732" NO="2" P_CHI2="1.0" P_Z="0.14751302785953074" STUDIES="1" TAU2="0.0" TOTAL_1="1139" TOTAL_2="1131" WEIGHT="14.155505426382023" Z="1.4483720477390334">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="2.494899395014925" CI_START="0.8717706785012268" EFFECT_SIZE="1.47478138664158" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.39705303770658873" LOG_CI_START="-0.059597742314514056" LOG_EFFECT_SIZE="0.16872764769603732" ORDER="23732" O_E="5.399559471365638" SE="0.2682389286422131" STUDY_ID="STD-TIM" TOTAL_1="1139" TOTAL_2="1131" VAR="13.89813059770174" WEIGHT="14.155505426382023"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7808800667168674" CI_END="2.4787194453354404" CI_START="1.3474877315320308" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.827578737701713" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.39422737378764017" LOG_CI_START="0.1295248197569612" LOG_EFFECT_SIZE="0.2618760967723007" METHOD="PETO" NO="25" P_CHI2="0.5951379060713756" P_Q="0.8092376497783487" P_Z="1.0528776757619539E-4" Q="0.058278610887460225" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2611" TOTAL_2="2596" WEIGHT="100.00000000000003" Z="3.878071520429288">
<NAME>Number of patients with gastrointestinal hemorrhage</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.722601455829407" CI_END="2.591470125756317" CI_START="1.3320026192518408" DF="3.0" EFFECT_SIZE="1.8579141517358415" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="52" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="0.41354620669514675" LOG_CI_START="0.12450507883240747" LOG_EFFECT_SIZE="0.2690256427637771" NO="1" P_CHI2="0.4364001409258267" P_Z="2.6379512996538014E-4" STUDIES="4" TAU2="0.0" TOTAL_1="1472" TOTAL_2="1465" WEIGHT="83.86813333058255" Z="3.648481270700953">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="18.87876476669767" CI_START="0.7399816589776671" EFFECT_SIZE="3.7376382478123897" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.275973575102053" LOG_CI_START="-0.13077904446294977" LOG_EFFECT_SIZE="0.5725972653195516" ORDER="23733" O_E="1.9308755760368665" SE="0.8263334522702559" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="1.464499847805928" WEIGHT="3.5406320662933393"/>
<DICH_DATA CI_END="360.75416435809115" CI_START="0.14188862356458143" EFFECT_SIZE="7.154502905580537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5572113530636638" LOG_CI_START="-0.8480524242831244" LOG_EFFECT_SIZE="0.8545794643902697" ORDER="23734" O_E="0.4918032786885246" SE="2.0002687991410566" STUDY_ID="STD-Smirne-1994" TOTAL_1="93" TOTAL_2="90" VAR="0.24993281375974202" WEIGHT="0.6042473381901855"/>
<DICH_DATA CI_END="2.389006717551552" CI_START="1.1719068299749766" EFFECT_SIZE="1.6732284031640043" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="49" LOG_CI_END="0.3782173709267173" LOG_CI_START="0.06889308537134116" LOG_EFFECT_SIZE="0.2235552281490292" ORDER="23735" O_E="15.59183673469387" SE="0.18169861651513602" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="30.289824633847957" WEIGHT="73.22986379389222"/>
<DICH_DATA CI_END="12.055761156384285" CI_START="1.1025987509889303" EFFECT_SIZE="3.645911023770352" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.0811946353341262" LOG_CI_START="0.04241749617977968" LOG_EFFECT_SIZE="0.5618060657569529" ORDER="23736" O_E="3.474418604651163" SE="0.6101828335690315" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="214" VAR="2.685839331031327" WEIGHT="6.493390132206796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5828556836809407" CI_START="0.7855669012269154" DF="0.0" EFFECT_SIZE="1.6776688698823967" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.5542293152709725" LOG_CI_START="-0.10481682323196645" LOG_EFFECT_SIZE="0.22470624601950306" NO="2" P_CHI2="1.0" P_Z="0.18137740845995054" STUDIES="1" TAU2="0.0" TOTAL_1="1139" TOTAL_2="1131" WEIGHT="16.131866669417477" Z="1.336525998922787">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="3.5828556836809407" CI_START="0.7855669012269154" EFFECT_SIZE="1.6776688698823967" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5542293152709725" LOG_CI_START="-0.10481682323196645" LOG_EFFECT_SIZE="0.22470624601950306" ORDER="23737" O_E="3.4524229074889874" SE="0.38712696408762615" STUDY_ID="STD-TIM" TOTAL_1="1139" TOTAL_2="1131" VAR="6.672570275544154" WEIGHT="16.131866669417477"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.323710643183894" CI_END="0.9468259859977991" CI_START="0.7500806542171199" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8427311878689425" ESTIMABLE="YES" EVENTS_1="1048" EVENTS_2="1142" I2="36.74599889684295" I2_Q="72.91903108429143" ID="CMP-001.26" LOG_CI_END="-0.023729831202839703" LOG_CI_START="-0.12489203554409692" LOG_EFFECT_SIZE="-0.07431093337346827" METHOD="PETO" NO="26" P_CHI2="0.17624275367014552" P_Q="0.05465360008701159" P_Z="0.003983445240219681" Q="3.692630064723943" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2611" TOTAL_2="2596" WEIGHT="100.0" Z="2.879469739078313">
<NAME>Number of patients with non-hemorrhagic gastrointestinal adverse events</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.631080578459951" CI_END="0.8905806551273617" CI_START="0.65452400022574" DF="3.0" EFFECT_SIZE="0.7634830796537806" ESTIMABLE="YES" EVENTS_1="701" EVENTS_2="788" I2="0.0" ID="CMP-001.26.01" LOG_CI_END="-0.05032674269085588" LOG_CI_START="-0.18407442401849425" LOG_EFFECT_SIZE="-0.11720058335467502" NO="1" P_CHI2="0.4520668067697222" P_Z="5.926427832083096E-4" STUDIES="4" TAU2="0.0" TOTAL_1="1472" TOTAL_2="1465" WEIGHT="57.2089589364003" Z="3.434959321343829">
<NAME>Stroke patients</NAME>
<DICH_DATA CI_END="2.150393407642303" CI_START="0.6517783990528839" EFFECT_SIZE="1.1838834286225042" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" LOG_CI_END="0.33251791998005603" LOG_CI_START="-0.18590003682513662" LOG_EFFECT_SIZE="0.07330894157745974" ORDER="23738" O_E="1.820276497695854" SE="0.3045212740376437" STUDY_ID="STD-Matias_x002d_Guiu-1994" TOTAL_1="111" TOTAL_2="106" VAR="10.783623681869559" WEIGHT="3.8078207494575045"/>
<DICH_DATA CI_END="2.2674275587440347" CI_START="0.40912873516744536" EFFECT_SIZE="0.9631561499532436" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.35553342083013145" LOG_CI_START="-0.38814001674607024" LOG_EFFECT_SIZE="-0.016303297957969455" ORDER="23739" O_E="-0.19672131147540917" SE="0.4368374584751472" STUDY_ID="STD-Smirne-1994" TOTAL_1="93" TOTAL_2="90" VAR="5.240349545643822" WEIGHT="1.850427307460832"/>
<DICH_DATA CI_END="0.8786736504862637" CI_START="0.6188115934081636" EFFECT_SIZE="0.7373828325525165" ESTIMABLE="YES" EVENTS_1="607" EVENTS_2="685" LOG_CI_END="-0.05617239695141545" LOG_CI_START="-0.20844155840830875" LOG_EFFECT_SIZE="-0.13230697767986216" ORDER="23740" O_E="-38.080208827717115" SE="0.08944365918428458" STUDY_ID="STD-TACIP" TOTAL_1="1052" TOTAL_2="1055" VAR="124.99737242594595" WEIGHT="44.13800058244111"/>
<DICH_DATA CI_END="1.085124161649187" CI_START="0.4612312614912809" EFFECT_SIZE="0.7074554303644316" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="64" LOG_CI_END="0.035479433699779794" LOG_CI_START="-0.33608126461878246" LOG_EFFECT_SIZE="-0.15030091545950133" ORDER="23741" O_E="-7.265116279069765" SE="0.21825659344744328" STUDY_ID="STD-TAPIRSS" TOTAL_1="216" TOTAL_2="214" VAR="20.9925528446675" WEIGHT="7.412710297040853"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1490883546436184" CI_START="0.8048339647884039" DF="0.0" EFFECT_SIZE="0.9616783954940481" ESTIMABLE="YES" EVENTS_1="347" EVENTS_2="354" I2="0.0" ID="CMP-001.26.02" LOG_CI_END="0.06035342334355624" LOG_CI_START="-0.09429370424524158" LOG_EFFECT_SIZE="-0.01697014045084268" NO="2" P_CHI2="1.0" P_Z="0.6670852794820981" STUDIES="1" TAU2="0.0" TOTAL_1="1139" TOTAL_2="1131" WEIGHT="42.7910410635997" Z="0.4301517217271261">
<NAME>AMI patients</NAME>
<DICH_DATA CI_END="1.1490883546436184" CI_START="0.8048339647884039" EFFECT_SIZE="0.9616783954940481" ESTIMABLE="YES" EVENTS_1="347" EVENTS_2="354" LOG_CI_END="0.06035342334355624" LOG_CI_START="-0.09429370424524158" LOG_EFFECT_SIZE="-0.01697014045084268" ORDER="23742" O_E="-4.735242290748886" SE="0.09084048826128747" STUDY_ID="STD-TIM" TOTAL_1="1139" TOTAL_2="1131" VAR="121.18282717247854" WEIGHT="42.7910410635997"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Triflusal versus placebo for secondary prevention of serious vascular events</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.189964273530868" CI_START="1.0066657564911488" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.2857294922138065" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.7151643682797092" LOG_CI_START="0.00288529557088188" LOG_EFFECT_SIZE="0.35902483192529555" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.048172583807292974" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="100.0" Z="1.9758428040094367">
<NAME>Primary outcome: serious vascular event</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23743" O_E="0.0" SE="0.0" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.189964273530868" CI_START="1.0066657564911488" EFFECT_SIZE="2.2857294922138065" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.7151643682797092" LOG_CI_START="0.00288529557088188" LOG_EFFECT_SIZE="0.35902483192529555" ORDER="23744" O_E="4.722419928825623" SE="0.4183962531474391" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="5.7124765028666955" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.236992177317504" CI_START="0.008657854046329792" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13916735168133526" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.3496644653868479" LOG_CI_START="-2.062589739775792" LOG_EFFECT_SIZE="-0.8564626371944721" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.16399597380418932" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="100.0" Z="1.391757070554828">
<NAME>Vascular mortality</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23745" O_E="0.0" SE="0.0" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.236992177317504" CI_START="0.008657854046329792" EFFECT_SIZE="0.13916735168133526" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3496644653868479" LOG_CI_START="-2.062589739775792" LOG_EFFECT_SIZE="-0.8564626371944721" ORDER="23746" O_E="-0.9822064056939501" SE="1.41697006096343" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="0.49805654509368996" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="0.0" Z="0.0">
<NAME>Ischemic stroke (non-fatal)</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23747" O_E="0.0" SE="0.0" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23748" O_E="0.0" SE="0.0" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.880426278823673" CI_START="1.2528439544381837" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.936000760793813" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.8376153459107797" LOG_CI_START="0.0978969816512044" LOG_EFFECT_SIZE="0.46775616378099205" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.01318468910097596" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="100.00000000000001" Z="2.4787413125129696">
<NAME>Acute myocardial infarction (non-fatal)</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23749" O_E="0.0" SE="0.0" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.880426278823673" CI_START="1.2528439544381837" EFFECT_SIZE="2.936000760793813" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.8376153459107797" LOG_CI_START="0.0978969816512044" LOG_EFFECT_SIZE="0.46775616378099205" ORDER="23750" O_E="5.704626334519572" SE="0.4345142288310322" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="5.296536807501713" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10688907354331911" CI_END="0.9950663863627732" CI_START="0.35709263494883087" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.596096366249027" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.0021479441092901322" LOG_CI_START="-0.44721910705747603" LOG_EFFECT_SIZE="-0.22468352558338303" METHOD="PETO" NO="5" P_CHI2="0.7437140991428838" P_Q="1.0" P_Z="0.04782931278221756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="100.0" Z="1.978881827103149">
<NAME>Number of patients with at least one adverse event</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8414923245626023" CI_START="0.18988540713028462" EFFECT_SIZE="0.7345460686077822" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4535464872663342" LOG_CI_START="-0.7215084099144391" LOG_EFFECT_SIZE="-0.13398096132405243" ORDER="23751" O_E="-0.6475409836065573" SE="0.6902330632195364" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="2.0989808791291775" WEIGHT="14.34638888999848"/>
<DICH_DATA CI_END="1.001325877312863" CI_START="0.330882197677044" EFFECT_SIZE="0.5756048183225834" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="40" LOG_CI_END="5.754398036105947E-4" LOG_CI_START="-0.4803265983844419" LOG_EFFECT_SIZE="-0.2398755792904157" ORDER="23752" O_E="-6.9217081850533795" SE="0.28248423773514336" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="12.531745328163813" WEIGHT="85.65361111000152"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0014078647217880104" CI_END="2.5006724152303925" CI_START="0.31727949625981466" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8907368209606658" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.39805680345546623" LOG_CI_START="-0.4985579926614543" LOG_EFFECT_SIZE="-0.05025059460299401" METHOD="PETO" NO="6" P_CHI2="0.9700691829536506" P_Q="1.0" P_Z="0.8261113714753868" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="99.99999999999999" Z="0.21969156888806882">
<NAME>Number of patients with serious adverse events related to medication</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.159671843371356" CI_START="0.057785264242645" EFFECT_SIZE="0.9359517312879969" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1806898003622937" LOG_CI_START="-1.238182896424134" LOG_EFFECT_SIZE="-0.028746548030920152" ORDER="23753" O_E="-0.032786885245901676" SE="1.4208577957053046" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="0.4953347207384489" WEIGHT="13.739969794282107"/>
<DICH_DATA CI_END="2.6854510255704236" CI_START="0.2908245131322135" EFFECT_SIZE="0.8837392076013839" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.42901723657803803" LOG_CI_START="-0.5363689902841888" LOG_EFFECT_SIZE="-0.053675876853075434" ORDER="23754" O_E="-0.38434163701067625" SE="0.5670726483977656" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="3.109729396248057" WEIGHT="86.26003020571788"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients with any intracranial hemorrhage or other major systemic hemorrhage</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23755" O_E="0.0" SE="0.0" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23756" O_E="0.0" SE="0.0" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.236992177317504" CI_START="0.008657854046329792" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13916735168133526" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.3496644653868479" LOG_CI_START="-2.062589739775792" LOG_EFFECT_SIZE="-0.8564626371944721" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.16399597380418932" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="100.0" Z="1.391757070554828">
<NAME>Number of patients with any minor hemorrhage</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23757" O_E="0.0" SE="0.0" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.236992177317504" CI_START="0.008657854046329792" EFFECT_SIZE="0.13916735168133526" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3496644653868479" LOG_CI_START="-2.062589739775792" LOG_EFFECT_SIZE="-0.8564626371944721" ORDER="23758" O_E="-0.9822064056939501" SE="1.41697006096343" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="0.49805654509368996" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3575351808260542" CI_END="1.1090375059326456" CI_START="0.4034438911219403" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6689053795520249" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.04494623356499015" LOG_CI_START="-0.3942168561600529" LOG_EFFECT_SIZE="-0.17463531129753138" METHOD="PETO" NO="9" P_CHI2="0.5498785603555855" P_Q="1.0" P_Z="0.11904889066242438" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="202" WEIGHT="100.0" Z="1.5587781786779982">
<NAME>Number of patients with non-hemorrhagic gastrointestinal adverse events</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Triflusal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triflusal</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7645711723040503" CI_START="0.117919134451611" EFFECT_SIZE="0.45615425605419724" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.24663917990513934" LOG_CI_START="-0.928415717275634" LOG_EFFECT_SIZE="-0.34088826868524735" ORDER="23759" O_E="-1.6475409836065573" SE="0.6902330632195364" STUDY_ID="STD-Auteri-1995" TOTAL_1="63" TOTAL_2="59" VAR="2.0989808791291775" WEIGHT="13.968036144461209"/>
<DICH_DATA CI_END="1.227705435281001" CI_START="0.4126866503518942" EFFECT_SIZE="0.7117988786904139" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="39" LOG_CI_END="0.0890941785496682" LOG_CI_START="-0.38437957951676566" LOG_EFFECT_SIZE="-0.14764270048354872" ORDER="23760" O_E="-4.395017793594306" SE="0.27812082922112485" STUDY_ID="STD-GEAIT" TOTAL_1="138" TOTAL_2="143" VAR="12.92804838555019" WEIGHT="86.03196385553879"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>